


(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 200012679 B2
(10) Patent No. 766193

- (54) Title
2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
- (51)⁷ International Patent Classification(s)
C07D 277/46 A61P 035/00
A61K 031/426 C07D 417/12
A61K 031/427
- (21) Application No: **200012679** (22) Application Date: **1999.10.27**
- (87) WIPO No: **WO00/26202**
- (30) Priority Data
- (31) Number (32) Date (33) Country
9823871 1998.10.30 GB
- (43) Publication Date : **2000.05.22**
(43) Publication Journal Date : **2000.07.20**
(44) Accepted Journal Date : **2003.10.09**
- (71) Applicant(s)
Pharmacia and Upjohn S.p.A.
- (72) Inventor(s)
Paolo Pevarello; Raffaella Amici; Gabriella Traquandi; Manuela Villa; Anna Vulpetti; Antonella Isacchi
- (74) Agent/Attorney
Griffith Hack,GPO Box 1285K,MELBOURNE VIC 3001
- (56) Related Art
WO 98/04536
EP 412404
US 4027031



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 277/46, 417/12, A61K 31/426, 31/427, A61P 35/00	A1	(11) International Publication Number: WO 00/26202 (43) International Publication Date: 11 May 2000 (11.05.00)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/EP99/08306 (22) International Filing Date: 27 October 1999 (27.10.99) (30) Priority Data: 9823871.0 30 October 1998 (30.10.98) GB (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): PEVARELLO, Paolo [IT/IT]; Piazza San Pietro in Ciel d'Oro, 7/A, I-27100 Pavia (IT). AMICI, Raffaella [IT/IT]; Via N. Rocca, 11, I-29100 Piacenza (IT). TRAQUANDI, Gabriella [IT/IT]; Via F. Cilea, 106, I-20151 Milano (IT). VILLA, Manuela [IT/IT]; Via San Bernardino, 12, I-22040 Lurago d'Erba (IT). VULPETTI, Anna [IT/IT]; Via Voltumo Portici/2 80, I-20047 Brugherio (IT). ISACCHI, Antonella [IT/IT]; Via Montecatini, 14, I-20144 Milano (IT). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </td> </tr> </table>			(21) International Application Number: PCT/EP99/08306 (22) International Filing Date: 27 October 1999 (27.10.99) (30) Priority Data: 9823871.0 30 October 1998 (30.10.98) GB (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): PEVARELLO, Paolo [IT/IT]; Piazza San Pietro in Ciel d'Oro, 7/A, I-27100 Pavia (IT). AMICI, Raffaella [IT/IT]; Via N. Rocca, 11, I-29100 Piacenza (IT). TRAQUANDI, Gabriella [IT/IT]; Via F. Cilea, 106, I-20151 Milano (IT). VILLA, Manuela [IT/IT]; Via San Bernardino, 12, I-22040 Lurago d'Erba (IT). VULPETTI, Anna [IT/IT]; Via Voltumo Portici/2 80, I-20047 Brugherio (IT). ISACCHI, Antonella [IT/IT]; Via Montecatini, 14, I-20144 Milano (IT).	(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(21) International Application Number: PCT/EP99/08306 (22) International Filing Date: 27 October 1999 (27.10.99) (30) Priority Data: 9823871.0 30 October 1998 (30.10.98) GB (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): PEVARELLO, Paolo [IT/IT]; Piazza San Pietro in Ciel d'Oro, 7/A, I-27100 Pavia (IT). AMICI, Raffaella [IT/IT]; Via N. Rocca, 11, I-29100 Piacenza (IT). TRAQUANDI, Gabriella [IT/IT]; Via F. Cilea, 106, I-20151 Milano (IT). VILLA, Manuela [IT/IT]; Via San Bernardino, 12, I-22040 Lurago d'Erba (IT). VULPETTI, Anna [IT/IT]; Via Voltumo Portici/2 80, I-20047 Brugherio (IT). ISACCHI, Antonella [IT/IT]; Via Montecatini, 14, I-20144 Milano (IT).	(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(54) Title: 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS				
 (I)				
(57) Abstract Compounds which are 2-amino-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from i) straight or branched C₁-C₈ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl; ii) C₃-C₆ cycloalkyl; iii) aryl or arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; R₁ is an optionally substituted group selected from: i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain; vi) an optionally protected amino acid residue; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.				

- 1 -

2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS.

5

The present invention relates to 2-amino-thiazole derivatives, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents, particularly in the treatment of cancer and cell proliferative disorders.

Several cytotoxic drugs such as, e.g. fluorouracil (5-FU), doxorubicin and camptothecins result to damage DNA or to affect cellular metabolic pathways and thus cause, in many cases, an indirect block of the cell cycle.

15

Therefore, by producing an irreversible damage to both normal and tumor cells, these agents result in a significant toxicity and side-effects.

20

In this respect, compounds capable of being highly specific antitumor agents by selectively leading to tumor cell arrest and apoptosis, with comparable efficacy but reduced toxicity than the currently available drugs, are desirable.

25

It is well known in the art that progression through the cell cycle is governed by a series of checkpoint controls, otherwise referred to as restriction points, which are regulated by a family of enzymes known as the cyclin-dependent kinases (cdk).

30

In their turn, the cdks themselves are regulated at many levels such as, for instance, binding to cyclins.

35

A normal progression through the cell cycle is controlled by the coordinated activation and inactivation of different cyclin/cdk complexes. In G1, both cyclin D/cdk4 and cyclin E/cdk2 are thought to mediate the onset of S-phase. Progression through S-phase requires the activity of cyclin A/cdk2 whereas the activation of cyclin A/cdc2 (cdk1) and cyclin B/cdc2 are required for the onset of metaphases.

For a general reference to cyclins and cyclin-dependent kinases see, for instance, Kevin R. Webster et al. in Exp. Opin. Invest. Drugs, 1998, Vol. 7(6), 865-887.

5 Checkpoint controls are defective in tumor cells due, in part, to dysregulation of cdk activity. For example, altered expression of cyclin E and cdk's has been observed in tumor cells, and deletion of the cdk inhibitor p27 KIP gene in mice has been shown to result in a higher incidence
10 of cancer.

Increasing evidence supports the idea that the cdks are rate-limiting enzymes in cell cycle progression and, as such, represent molecular targets for therapeutic intervention. In particular, the direct inhibition of
15 cdk/cyclin kinase activity should be helpful in restricting the unregulated proliferation of a tumor cell.

It has now been found that the 2-amino-1,3-thiazoles of the invention are endowed with cdk/cyclin kinase inhibitory
20 activity and are thus useful in therapy as antitumor agents whilst lacking, in terms of both toxicity and side effects, the aforementioned drawbacks known for currently available antitumor drugs.

More specifically, the compounds of this invention are
25 useful in the treatment of a variety of cancers including, but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous
30 cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of
35 myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central

and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, 5 thyroid follicular cancer and Kaposi's sarcoma.

Due to the key role of cdks in the regulation of cellular proliferation, these 2-amino-1,3-thiazole derivatives are also useful in the treatment of a variety of cell 10 proliferative disorders such as, for instance, benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical 15 stenosis and restenosis.

The compounds of the invention can be useful in the treatment of Alzheimer's disease, as suggested by the fact that cdk5 is involved in the phosphorylation of tau protein (*J.Biochem.*, 117, 741-749, 1995).

20 The compounds of this invention, as modulators of apoptosis, could be useful in the treatment of cancer, viral infections, prevention of AIDS development in HIV-infected individuals, autoimmune diseases and neurodegenerative disorder.

25 The compounds of this invention could be useful in inhibiting tumor angiogenesis and metastasis.

The compounds of this invention may also act as inhibitors of other protein kinases, e.g. protein kinase C, her2, 30 raf1, MEK1, MAP kinase, EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, weel kinase, Src, Abl and thus be effective in the treatment of diseases associated with other protein kinases.

35 Several 2-amino-1,3-thiazole derivatives are known in the art. Just few examples among them are 2-acetamido-, 2-propionamido- or 2-butyramido-1,3-thiazole derivatives further substituted by halogen atoms in position 5 of the

thiazole ring, which are reported as herbicides in JP 73027467 (Sankyo Co. Ltd.) or US 3,374,082 (The Upjohn Co.); 5-nitro-2-benzamido-1,3-thiazole is reported as pesticide in Ann. Rech. Vet., 22(4), 359-63, 1991; 5-phenyl-2-acetamido-1,3-thiazoles further substituted onto phenyl ring are reported as synthetic intermediates (Chemical Abstracts, 1980, 92:128793); and 5-dimethylaminomethyl- or 5-diethylaminomethyl-2-acetamido-1,3-thiazole, both reported as herbicides in JP 71018564 (Japan Gas Chem Co.).

Several other 2-amino-1,3-thiazole derivatives have been reported in the art as useful therapeutic agents.


In particular, 5-methyl-1,3-thiazoles further substituted in position 2 of the thiazole ring by a benzothiazinyl-carbonylamino moiety, or derivatives thereof, have been described as cyclooxygenase inhibitors; see, for instance, C.A. 126(1997):301540.

2-Benzamido-1,3-thiazoles are disclosed in EP-A-261503 (Valeas S.p.A.) as antiallergic agents; 5-Alkyl-2-phenylalkylcarbonylamino-1,3-thiazoles further substituted onto the phenyl ring with an alkenylcarbonyl or alkynylcarbonyl moieties are disclosed in WO 98/04536 (Otsuka Pharmaceutical Co.) as protein kinase C inhibitors.

5-Arylthio-2-acylamino-1,3-thiazole derivatives are disclosed in EP-A-412404 (Fujisawa Pharm. Co.) as antitumor agents.

In addition, among the compounds reported in the art as therapeutic agents, DE 2128941 (Melle-Bezons) discloses 2-aminomethylcarbonylamino-5-chloro-1,3-thiazoles as antiinflammatory, sedative and analgesic agents; the compound 2-diethylaminomethylcarbonylamino-5-chloro-1,3-thiazole being specifically exemplified therein.

Accordingly, the present invention provides the use of a compound which is a 2-amino-1,3-thiazole derivative of formula (I)



wherein

R is isopropyl;

R₁ is an optionally further substituted group selected from:

- 10
- i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl;
 - ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;
 - iii) aryl or arylcarbonyl;
 - 15 iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;
 - v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;
 - vi) an optionally protected amino acid residue;
 - 20 or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for treating cell proliferative disorders associated with an altered cell cycle dependent kinase activity.

25 According to a preferred embodiment of the invention, the said cell proliferative disorder is selected from the group consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative disorders.

30 Preferably, the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma,

35 teratocarcinoma, osteosarcoma, xenoderoma pigmentosum,


keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

According to another preferred embodiment of the invention, the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.

In addition, being useful in the treatment of cell proliferative disorders associated with an altered cell dependent kinase activity, hence cell cycle inhibition or cdk-cyclin dependent inhibition, the compounds of formula (I) of the invention also enable tumor angiogenesis and metastasis inhibition.

As above reported, some of the compounds of formula (I) of the invention have been reported in the art as useful therapeutic agents, for instance as antiinflammatory, sedative and analgesic agents.

Therefore, it is a further object of the present invention to provide a compound which is a 2-amino-1,3-thiazole derivative of formula (I)



wherein

R is isopropyl;


R₁ is an optionally further substituted group selected from:

- i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl;
- ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;

- iii) aryl or arylcarbonyl;
 - iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;
 - v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;
 - vi) an optionally protected amino acid residue;
- or a pharmaceutically acceptable salt thereof; for use as a medicament; provided that R₁ is not a methyl group.

Among the compounds of formula (I) above reported, several derivatives result to be novel.

Therefore, the present invention further provides a compound which is a 2-amino-1,3-thiazole derivative of formula (I)



wherein

R is isopropyl;

R₁ is an optionally further substituted group selected from:


- i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl;
 - ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;
 - iii) aryl or arylcarbonyl;
 - iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;
 - v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;
 - vi) an optionally protected amino acid residue;
- or a pharmaceutically acceptable salt thereof; provided that:
- a) R₁ is not methyl.

The compounds of formula (I) may have asymmetric carbon atoms and may therefore exist either as racemic admixtures or as individual optical isomers.

5 Accordingly, all the possible isomers and their admixtures
and of both the metabolites and the pharmaceutically
acceptable bio-precursors (otherwise referred to as pro-
drugs) of the compounds of formula (I), as well as the
uses thereof, are also within the scope of the present
10 invention.

In the present description, unless otherwise specified,
with the term halogen atom we intend a chlorine, bromine,
fluorine or iodine atom.

15 With the term optionally substituted amino group we intend
an amino group wherein one or both hydrogen atoms are
optionally replaced by other substituents which are the
same or different, as set forth below.



With the term straight or branched C₁-C₈ alkyl we intend a group such as, for instance, methyl, ethyl, n.propyl, isopropyl, n.butyl, isobutyl, sec-butyl, tert-butyl, n.pentyl, n.hexyl, n.heptyl, n.octyl and the like.

5

With the term straight or branched C₂-C₆ alkenyl or alkynyl we intend a group such as, for instance, vinyl, allyl, isopropenyl, 1-, 2- or 3-butenyl, isobutylenyl, pentenyl, hexenyl, ethynyl, 1- or 2-propynyl, butynyl, pentynyl, hexynyl and the like.

10

With the term C₃-C₆ cycloalkyl we intend a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.

15 With the term aryl, either as such or as arylalkyl, arylalkenyl, arylcarbonyl and the like, we intend a mono-, bi- or poly- either carbocyclic as well as heterocyclic hydrocarbon with from 1 to 4 ring moieties, either fused or linked to each other by single bonds, wherein at least one
20 of the carbocyclic or heterocyclic rings is aromatic.

Examples of aryl groups are phenyl, indanyl, biphenyl, α - or β -naphthyl, fluorenyl, 9,10-dihydroanthracenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, 1,2-methylenedioxyphenyl, thiazolyl, isothiazolyl,
25 pyrrolyl, pyrrolyl-phenyl, furyl, phenyl-furyl, benzotetrahydrofuran, oxazolyl, isoxazolyl, pyrazolyl, chromenyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl, tetrazolyl, tetrazolylphenyl, pyrrolidinyl-tetrazolyl, isoindolinyl-phenyl, quinolinyl,
30 isoquinolinyl, 2,6-diphenyl-pyridyl, quinoxalinyl, pyrazinyl, phenyl-quinolyl, benzofurazanyl, 1,2,3-triazole, 1-phenyl-1,2,3-triazole, and the like.

With the term 3 to 6 membered carbocycle, hence
35 encompassing but not limited to C₃-C₆ cycloalkyl groups, we also intend an unsaturated carbocyclic hydrocarbon such as, for instance, cyclopentylene or cyclohexylene.

With the term 5 to 7 membered heterocycle, hence encompassing aromatic heterocycles also referred to as aryl groups, we further intend a saturated or partially unsaturated 5 to 7 membered carbocycle wherein one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen and sulphur.

Examples of 5 to 7 membered heterocycles, optionally benzocondensed or further substituted, are 1,3-dioxolane, pyran, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, piperidine, piperazine, N-alkyl-piperazine, morpholine, tetrahydrofuran and the like.

With the term amino acid residue we intend the residue of a natural α -amino acid of formula HOOC-R_1 , wherein R_1 is bonded to the thiazole- NH-C(=O)- moiety and is represented by a $-\text{CH(Z)NHY}$ group wherein Z is the characterising portion of the amino acid and Y is hydrogen or a suitable amino protecting group such as, for instance, tert-butoxycarbonyl or benzyloxycarbonyl.

Examples of α -amino acids are alanine, isoleucine, glycine, lysine, arginine, cystine, histidine, leucine, proline and the like.

According to the above indicated substituent meanings, any of the above R and R_1 groups may be optionally substituted in any of the free positions by one or more groups, for instance 1 to 6 groups, selected from: halogen, nitro, oxo groups ($=\text{O}$), carboxy, cyano, alkyl, perfluorinated alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycyl; amino groups and derivatives thereof such as, for instance, alkylamino, alkoxycarbonylalkylamino, dialkylamino, arylamino, diarylamino or arylureido; carbonylamino groups and derivatives thereof such as, for instance, hydrogenocarbonylamino (HCONH-), alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino; oxygen-substituted oximes such as, for instance, alkoxycarbonylalkoxyimino or alkoxyimino; hydroxy

groups and derivatives thereof such as, for instance, alkoxy, aryloxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy; carbonyl groups and derivatives thereof such as, for instance, alkylcarbonyl, arylcarbonyl, 5 alkoxy carbonyl, aryloxy carbonyl, cycloalkyloxy carbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl; sulfurated derivatives such as, for instance, alkylthio, arylthio, alkylsulphonyl, arylsulphonyl, alkylsulphinyl, arylsulphinyl, arylsulphonyloxy, aminosulfonyl, 10 alkylaminosulphonyl or dialkylaminosulphonyl. In their turn, whenever appropriate, each of the above possible substituents on R and R₁ may be further substituted by one or more of the aforementioned groups.

Examples of compounds of formula (I) wherein R and R₁ groups 15 are substituted by one or more of the aforementioned substituents which, in their turn, are optionally further substituted as set forth above, are given below.

Pharmaceutically acceptable salts of the compounds of 20 formula (I) are the acid addition salts with inorganic or organic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, 25 isethionic and salicylic acid, as well as the salts with inorganic or organic bases, e.g. alkali or alkaline-earth metals, especially sodium, potassium, calcium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines, preferably methylamine, ethylamine, diethylamine, 30 triethylamine or piperidine.


The compounds of formula (I) may have asymmetric carbon atoms and may therefore exist either as racemic admixtures or as individual optical isomers.

35 Accordingly, the use as an antitumor agent of all the possible isomers and their admixtures and of both the metabolites and the pharmaceutically acceptable bio-precursors (otherwise referred to as pro-drugs) of the

compounds of formula (I) are also within the scope of the present invention.

Preferred compounds of formula (I), according to the present invention, are 2-amino-1,3-thiazole derivatives wherein R is isopropyl and R₁ is an optionally substituted group selected from straight or branched C₁-C₄ alkyl or alkenyl, aryl or arylalkyl with from 1 to 4 carbon atoms within the alkyl chain or it is an optionally protected amino acid residue.

Another class of preferred compounds of the invention are the compounds of formula (I)



wherein

R is isopropyl;

20 R₁ is an optionally further substituted group selected from:

- i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl;
- ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;
- 25 iii) aryl or arylcarbonyl;
- iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;
- v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;
- 30 vi) an optionally protected amino acid residue; or a pharmaceutically acceptable salt thereof; provided that:

a) R₁ is not methyl.

35 Examples of preferred compounds of the invention, whenever appropriate in the form of pharmaceutically acceptable

salts, e.g. hydrobromide or hydrochloride salt, are the following:

1. 2-N-[2-(3-pyridyl)-acetyl-amino]-5-isopropyl-thiazole;
2. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-hydroxyphenyl)acetamide;
3. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methoxyphenyl)acetamide;
4. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-chlorophenyl)acetamide;
5. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-hydroxyphenyl)acetamide;
6. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-dihydroxyphenyl)acetamide;
7. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetamide;
8. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methoxyphenyl)acetamide;
9. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-chlorophenyl)acetamide;
10. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-acetamide;
11. N-(5-isopropyl-thiazol-2-yl)-4-sulfamoyl-benzamide;
12. N-(5-isopropyl-1,3-thiazol-2-yl)-butanamide;
13. 2-[3-(2-chloroethoxy)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
14. 2-(4-aminophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
15. 4-amino-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
16. 2-(2-amino-1,3-thiazol-4-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
17. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(4-morpholinyl)propoxy]phenyl}acetamide;
18. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[2-(4-morpholinyl)ethoxy]phenyl}acetamide;
19. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(1-pirrolidinyl)propoxy]phenyl}acetamide;
20. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl}acetamide;

21. 2-{3-[2-(dimethylamino)ethoxy]phenyl}-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
22. 2-{3-[3-(dimethylamino)propoxy]phenyl}-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 5 23. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(2-methoxyethoxy)-phenyl]acetamide
24. 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-methyl-1-piperazinyl)benzamide
25. 2-anilino-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 10 26. (R)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylpropanamide
27. (S)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylpropanamide
28. N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 15 29. 2,5-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
30. 3,5-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
31. 3,4-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 20 32. 2,4-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
33. 2,3-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 25 34. 3-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
35. 2-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
36. 4-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
37. 3-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
38. 4-chloro-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 30 39. 5-bromo-2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
40. 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
41. 2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 35 42. 4-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
43. 3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
44. 2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide

45. 4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
46. 2,4-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
47. 3,4-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
5 48. 2,3,4,5,6-pentafluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
49. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methyl-3-nitrobenzamide
10 50. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-nitrobenzamide
51. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-nitrobenzamide
52. N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dimethyl-4-nitrobenzamide
15 53. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxy-2-nitrobenzamide
54. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-2-nitrobenzamide
20 55. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxy-3-nitrobenzamide
56. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-4-nitrobenzamide
57. N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dinitrobenzamide
25 58. 5-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-nitrophenyl octanoate
59. N-(5-isopropyl-1,3-thiazol-2-yl)-3-nitrobenzamide
60. N-(5-isopropyl-1,3-thiazol-2-yl)-2-nitrobenzamide
61. N-(5-isopropyl-1,3-thiazol-2-yl)-4-nitrobenzamide
30 62. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(methylsulfonyl)-3-nitrobenzamide
63. 4-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-3-nitrobenzamide
64. 6-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-3-nitrobenzamide
35 65. 4-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-nitrobenzamide

66. 2-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-nitrobenzamide
67. 5-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitrobenzamide
- 5 68. 2-bromo-N- (5-isopropyl-1,3-thiazol-2-yl) -5-nitrobenzamide
69. 4-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-nitrobenzamide
70. 4-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitrobenzamide
- 10 71. N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitro-4-(trifluoromethyl) benzamide
72. N- (5-isopropyl-1,3-thiazol-2-yl) -3,5-bis (trifluoromethyl) benzamide
- 15 73. N- (5-isopropyl-1,3-thiazol-2-yl) -2,6-bis (trifluoromethyl) benzamide
74. N- (5-isopropyl-1,3-thiazol-2-yl) -2-(trifluoromethyl) benzamide
75. N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl) benzamide
- 20 76. 3-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-(trifluoromethyl) benzamide
77. 2-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl) benzamide
- 25 78. 5-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl) benzamide
79. 2-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-(trifluoromethyl) benzamide
80. 4-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl) benzamide
- 30 81. methyl 4- { [(5-isopropyl-1,3-thiazol-2-yl) amino] carbonyl } benzoate
82. methyl 2- { [(5-isopropyl-1,3-thiazol-2-yl) amino] carbonyl } benzoate
- 35 83. 4-cyano-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
84. 3-cyano-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
85. N- (5-isopropyl-1,3-thiazol-2-yl) -3-methylbenzamide

86. N-(5-isopropyl-1,3-thiazol-2-yl)-2-methylbenzamide
87. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methylbenzamide
88. N-(5-isopropyl-1,3-thiazol-2-yl)-4-vinylbenzamide
89. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(2-
5 phenylethynyl) benzamide
90. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-4-
methylbenzamide
91. 2-benzyl-N-(5-isopropyl-1,3-thiazol-2-yl) benzamide
92. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenethylbenzamide
10 93. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylbenzamide
94. N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenylbenzamide
95. 4-(tert-butyl)-N-(5-isopropyl-1,3-thiazol-2-
yl) benzamide
96. N-(5-isopropyl-1,3-thiazol-2-yl)-4-isopropylbenzamide
15 97. N-(5-isopropyl-1,3-thiazol-2-yl)-4-pentylbenzamide
98. 3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-
methylbenzamide
99. N-(5-isopropyl-1,3-thiazol-2-yl)-3,4-
dimethylbenzamide
20 100. N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-
dimethylbenzamide
101. 4-acetyl-N-(5-isopropyl-1,3-thiazol-2-yl) benzamide
102. N-(5-isopropyl-1,3-thiazol-2-yl)-4-
(methylsulfonyl) benzamide
25 103. 5-(aminosulfonyl)-2,4-dichloro-N-(5-isopropyl-1,3-
thiazol-2-yl) benzamide
104. 5-(aminosulfonyl)-4-chloro-N-(5-isopropyl-1,3-
thiazol-2-yl) benzamide
105. 3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-
30 methoxybenzamide
106. 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-
methoxybenzamide
107. 5-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
methoxybenzamide

108. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxybenzamide
109. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxybenzamide
110. N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxybenzamide
111. N-(5-isopropyl-1,3-thiazol-2-yl)-3,4-
5 dimethoxybenzamide
112. N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-
dimethoxybenzamide
113. N-(5-isopropyl-1,3-thiazol-2-yl)-2,4-
dimethoxybenzamide
10 114. N-(5-isopropyl-1,3-thiazol-2-yl)-2,3-
dimethoxybenzamide
115. N-(5-isopropyl-1,3-thiazol-2-yl)-3-phenoxybenzamide
116. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenoxybenzamide
117. N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenoxybenzamide
15 118. 2-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
119. 4-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
120. N-(5-isopropyl-1,3-thiazol-2-yl)-3,4,5-
trimethoxybenzamide
121. 3,4-diethoxy-N-(5-isopropyl-1,3-thiazol-2-
20 yl)benzamide
122. 3,4,5-triethoxy-N-(5-isopropyl-1,3-thiazol-2-
yl)benzamide
123. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-4-
(methoxymethoxy)benzamide
25 124. 4-butoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
125. N-(5-isopropyl-1,3-thiazol-2-yl)-4-propoxybenzamide
126. 4-isopropoxy-N-(5-isopropyl-1,3-thiazol-2-
yl)benzamide
127. N-(5-isopropyl-1,3-thiazol-2-yl)-1,3-benzodioxole-5-
30 carboxamide
128. 4-(benzyloxy)-N-(5-isopropyl-1,3-thiazol-2-
yl)benzamide
129. 4-(2-cyclohexen-1-yloxy)-N-(5-isopropyl-1,3-thiazol-
2-yl)benzamide
35 130. N-(5-isopropyl-1,3-thiazol-2-yl)-4-
(trifluoromethoxy)benzamide

131. 4-(difluoromethoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
132. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(methylsulfanyl)benzamide
- 5 133. 2-[(4-chlorophenyl)sulfinyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
134. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[(4-nitrophenyl)sulfinyl]benzamide
135. N-(5-isopropyl-1,3-thiazol-2-yl)-4-[(4-methylphenyl)sulfonyl]-3-nitrobenzamide
- 10 136. N-(5-isopropyl-1,3-thiazol-2-yl)-3-[(trifluoromethyl)sulfanyl]benzamide
137. N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxy-4-(methylsulfanyl)benzamide
- 15 138. 2-[(2-cyanophenyl)sulfanyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
139. N-1~,N-1~-diethyl-3,6-difluoro-N-2~-(5-isopropyl-1,3-thiazol-2-yl)phthalamide
140. 4-formyl-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 20 141. 2-formyl-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
142. 4-{[(2,5-dimethoxyanilino)carbonyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
143. 4-(hydroxymethyl)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 25 144. 4-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-nitrobenzyl acetate
145. 4-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-nitrobenzyl 4-(acetylamino)-3-iodobenzoate
146. 4-(acetylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 30 147. N-(5-isopropyl-1,3-thiazol-2-yl)-4-[(2-phenylacetyl)amino]benzamide
148. 4-(acetylamino)-3-iodo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 35 149. 4-amino-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
150. 4-(dimethylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide

151. 3-(dimethylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
152. 2-(methylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 5 153. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(trifluoromethyl)anilino]benzamide
154. 3-{[(5-bromo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 10 155. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(1H-pyrrol-1-yl)benzamide
156. 2,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)isonicotinamide
157. 2-(4-bromophenyl)-6-(4-iodophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)isonicotinamide
- 15 158. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(trifluoromethyl)anilino]nicotinamide
159. 2,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide
- 20 160. 5,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide
161. 2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-6-methylnicotinamide
162. 2,6-dichloro-5-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide
- 25 163. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenoxy nicotinamide
164. N-(5-isopropyl-1,3-thiazol-2-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide
- 30 165. N-(5-isopropyl-1,3-thiazol-2-yl)-2,6-dimethoxynicotinamide
166. N-(5-isopropyl-1,3-thiazol-2-yl)-2-quinoxalinecarboxamide
167. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-pyrazinecarboxamide
- 35 168. N-(5-isopropyl-1,3-thiazol-2-yl)-8-quinolinecarboxamide

169. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-4-quinolinecarboxamide
170. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-1-phenyl-1H-pyrazole-4-carboxamide
- 5 171. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-1H-pyrazole-3-carboxamide
172. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-pyrazole-4-carboxamide
173. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide
- 10 174. 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methyl-1,3-thiazole-5-carboxamide
175. N-(5-isopropyl-1,3-thiazol-2-yl)-9H-fluorene-1-carboxamide
- 15 176. N-(5-isopropyl-1,3-thiazol-2-yl)-7-methoxy-1-benzofuran-2-carboxamide
177. N-(5-isopropyl-1,3-thiazol-2-yl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide
- 20 178. 2-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)-1-naphthamide
179. 4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-1-naphthamide
180. N-(5-isopropyl-1,3-thiazol-2-yl)-2-naphthamide
- 25 181. N-(5-isopropyl-1,3-thiazol-2-yl)-9,10-dioxo-9,10-dihydro-2-anthracenecarboxamide
182. N-(5-isopropyl-1,3-thiazol-2-yl)-9-oxo-9H-fluorene-4-carboxamide
183. N-(5-isopropyl-1,3-thiazol-2-yl)-9-oxo-9H-fluorene-1-carboxamide
- 30 184. N-(5-isopropyl-1,3-thiazol-2-yl)-8-oxo-5,6,7,8-tetrahydro-2-naphthalenecarboxamide
185. N-(5-isopropyl-1,3-thiazol-2-yl)-1,3-dioxo-1,3-dihydro-2-benzofuran-5-carboxamide
- 35 186. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-5-carboxamide

187. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-4-carboxamide
188. N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-2-phenyl-1H-indole-5-carboxamide
- 5 189. 2-butyl-N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-1H-indole-5-carboxamide
190. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-6-carboxamide
191. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methoxy-1H-indole-2-carboxamide
- 10 192. 1-allyl-2-butyl-N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-5-carboxamide
193. N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-1H-indole-2-carboxamide
- 15 194. 1-benzyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-1H-indole-5-carboxamide
195. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-1,2,3-benzotriazole-5-carboxamide
196. N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dimethyl-4-isoxazolecarboxamide
- 20 197. N-(5-isopropyl-1,3-thiazol-2-yl)-3-thiophenecarboxamide
198. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-thiophenecarboxamide
- 25 199. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-thiophenecarboxamide
200. 5-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)-2-thiophenecarboxamide
201. N-(5-isopropyl-1,3-thiazol-2-yl)-3-[(2,3,3-trichloroacryloyl)amino]-2-thiophenecarboxamide
- 30 202. 5-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide
203. N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide
204. N-(5-isopropyl-1,3-thiazol-2-yl)-5-(4-nitrophenyl)-2-furamide
- 35 205. N-(5-isopropyl-1,3-thiazol-2-yl)-5-(2-nitrophenyl)-2-furamide

206. 5-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-
2-furamide
207. N-(5-isopropyl-1,3-thiazol-2-yl)-5-[3-
(trifluoromethyl)phenyl]-2-furamide
- 5 208. 5-(4-chloro-2-nitrophenyl)-N-(5-isopropyl-1,3-
thiazol-2-yl)-2-furamide
209. N-(5-isopropyl-1,3-thiazol-2-yl)-5-(4-methyl-2-
nitrophenyl)-2-furamide
210. 5-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5-
10 isopropyl-1,3-thiazol-2-yl)-2-furamide
211. tert-butyl (1R)-2-[(5-isopropyl-1,3-thiazol-2-
yl)amino]-2-oxo-1-phenylethylcarbamate
212. (1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-
phenylethyl acetate
- 15 213. (1S)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-
phenylethyl acetate
214. (R,S)-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
phenylacetamide
215. (R)-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
20 phenylacetamide
216. (S)-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
phenylacetamide
217. 2-(acetylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
phenylacetamide
- 25 218. (R,S)-2-(methoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
phenylacetamide
219. (R)-2-(methoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
phenylacetamide
220. (S)-2-(methoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
30 phenylacetamide
221. 3,3,3-trifluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-
methoxy-2-phenylpropanamide
222. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(1-
naphthyl)acetamide
- 35 223. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-
naphthyl)acetamide

224. 2-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
225. 2-(1,3-benzodioxol-4-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 5 226. 2-(2,4-dinitrophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
227. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-methyl-1H-indol-3-yl)acetamide
228. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(1-methyl-1H-indol-3-yl)acetamide
- 10 229. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(5-methoxy-1H-indol-3-yl)acetamide
230. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(5-benzyloxy-1H-indol-3-yl)acetamide
- 15 231. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methoxy-2-methyl-1H-indol-3-yl)acetamide
232. 2-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxoacetamide
233. 2-(5-bromo-1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 20 234. 2-(5-fluoro-1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
235. 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 25 236. 3-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
237. 4-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)butanamide
238. N-(5-isopropyl-1,3-thiazol-2-yl)-3-(2-thienyl)propanamide
- 30 239. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-thienyl)acetamide
240. N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxo-2-(2-thienyl)acetamide
- 35 241. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-thienyl)acetamide

242. 2-(5-chloro-1-benzothiophen-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
243. 2-(1-benzothiophen-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 5 244. 2-[2-(formylamino)-1,3-thiazol-4-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)-2-(methoxyimino)acetamide
245. 2-{2-[(2-chloroacetyl)amino]-1,3-thiazol-4-yl}-N-(5-isopropyl-1,3-thiazol-2-yl)-2-(methoxyimino)acetamide
246. 2-chloro-N-(4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}-1,3-thiazol-2-yl)acetamide
- 10 247. ethyl 2-({[2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-(1H-pyrazol-3-yl)ethylidene]amino}oxy)acetate
248. 2-(2-furyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxoacetamide
- 15 249. 2-(5-bromo-3-pyridinyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
250. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide
251. N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenyl-3-butenamide
- 20 252. N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxo-4-(4-methylphenyl)butanamide
253. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-nitrophenyl)butanamide
- 25 254. N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenylbutanamide
255. benzyl 4-[(5-isopropyl-1,3-thiazol-2-yl)amino]-4-oxobutylcarbamate
256. methyl 5-[(5-isopropyl-1,3-thiazol-2-yl)amino]-5-oxopentanoate
- 30 257. 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)butanamide
258. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-methoxy-1-naphthyl)-4-oxobutanamide
259. 3-(2-chlorophenoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
- 35 260. 3-(4-methylphenoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide

261. 3-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
262. 3-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
- 5 263. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methylpentanamide
264. 3-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
265. 3-(4-methoxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
- 10 266. 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
267. 3-phenyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
268. 2-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
269. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methylbutanamide
- 15 270. N-(5-isopropyl-1,3-thiazol-2-yl)-5-oxo-5-phenylpentanamide
271. 2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethyl acetate
272. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide
- 20 273. 1-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)cyclopentanecarboxamide
274. 1-phenyl-N-(5-isopropyl-1,3-thiazol-2-yl)cyclopentanecarboxamide
- 25 275. 2-(3-bromo-4-methoxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
276. 2-(2-nitro-4-trifluoromethylphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
277. 5-cyclohexyl 1-(4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}benzyl) (2S)-2-[(tert-butoxycarbonyl)amino]pentanedioate
- 30 278. 2-(5,6-dimethyl-1H-benzimidazol-1-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
279. 2-[5-(4-chlorophenyl)-2H-1,2,3,4-tetraazol-2-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 35 280. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[5-(1-pyrrolidinyl)-2H-1,2,3,4-tetraazol-2-yl]acetamide

281. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methyl-1-benzothiophen-2-yl)acetamide
282. N-(5-isopropyl-1,3-thiazol-2-yl)-4,4-bis(4-methylphenyl)-3-butenamide
- 5 283. 2-cyclopropyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
284. N-{4-bromo-6-[(5-isopropyl-1,3-thiazol-2-yl)amino]-6-oxohexyl}benzamide
285. 2-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 10 286. benzyl 6-[(5-isopropyl-1,3-thiazol-2-yl)amino]-6-oxohexylcarbamate
287. N-1--(5-isopropyl-1,3-thiazol-2-yl)-N-4--(2-propynyl)-2-butenediamide
- 15 288. 4-(2,4-dimethylphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide
289. 4-(4-benzyloxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide
290. 4-(thiophen-2-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide
- 20 291. benzyl 2-[[(benzyloxy) carbonyl] amino]-5-[(5-isopropyl-1,3-thiazol-2-yl)amino]-5-oxopentanoate
292. 4-(1H-indol-3-yl)-N-{3-[(5-isopropyl-1,3-thiazol-2-yl)amino]-3-oxopropyl}butanamide
- 25 293. 4-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}phenyl 4-chlorobenzenesulfonate
294. N-(5-isopropyl-1,3-thiazol-2-yl)-4-{[(2-methoxyanilino) carbonyl] amino}benzamide
295. 4-{[2-(isopropylsulfonyl)acetyl] amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 30 296. N-(5-isopropyl-1,3-thiazol-2-yl)-4-{[2-(phenylsulfonyl)acetyl] amino}benzamide
297. 4-[(diethylamino) sulfonyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 35 298. 2-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
299. 3,5-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide

300. 3- { [(2-fluoroanilino) carbonyl] amino} -N- (5-isopropyl-
1,3-thiazol-2-yl) benzamide
301. N- (5-isopropyl-1,3-thiazol-2-yl) -1-phenyl-5-propyl-
1H-pyrazole-4-carboxamide
- 5 302. 3-chloro-4- (isopropylsulfonyl) -N- (5-isopropyl-1,3-
thiazol-2-yl) -5- (methylsulfonyl) -2-
thiophenecarboxamide
303. 3-iodo-4- (isopropylsulfonyl) -N- (5-isopropyl-1,3-
thiazol-2-yl) -5- (methylsulfonyl) -2-
10 thiophenecarboxamide
304. 2- { [(4-chlorophenyl) sulfonyl] methyl} -N- (5-isopropyl-
1,3-thiazol-2-yl) -4-methyl-1,3-thiazole-5-carboxamide
305. 5- (4-chlorophenyl) -N- (5-isopropyl-1,3-thiazol-2-yl) -
2- (trifluoromethyl) -3-furamide
- 15 306. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2,3,4,5,6-
pentafluorophenyl) acetamide
307. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2-
fluorophenyl) acetamide
308. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2-
20 bromophenyl) acetamide
309. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2-
chlorophenyl) acetamide
310. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2-
nitrophenyl) acetamide
- 25 311. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2-
trifluoromethylphenyl) acetamide
312. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2-
methoxyphenyl) acetamide
313. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2,5-
30 dimethoxyphenyl) acetamide
314. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2,5-
difluorophenyl) acetamide
315. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (3,4,5-
trimethoxyphenyl) acetamide
- 35 316. N- (5-isopropyl-1,3-thiazol-2-yl) -2- (2,6-
dichlorophenyl) acetamide

317. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-chloro-6-fluorophenyl)acetamide
318. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,5-dimethoxyphenyl)acetamide
- 5 319. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,5-difluorophenyl)acetamide
320. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,5-bis-trifluoromethylphenyl)acetamide
321. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methylthiophenyl)acetamide
- 10 322. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methoxyphenyl)acetamide
323. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-bromophenyl)acetamide
- 15 324. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-chlorophenyl)acetamide
325. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-fluorophenyl)acetamide
326. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)acetamide
- 20 327. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-trifluoromethylphenyl)acetamide
328. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methylphenyl)acetamide
- 25 329. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-dimethylaminophenyl)acetamide
330. 2-[1,1'-biphenyl]-4-yl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
331. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-trifluoromethylphenyl)acetamide
- 30 332. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-bromophenyl)acetamide
333. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-chlorophenyl)acetamide
- 35 334. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-nitrophenyl)acetamide

335. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methoxyphenyl)acetamide
336. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-dinitrophenyl)acetamide
- 5 337. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-dichlorophenyl)acetamide
338. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-difluorophenyl)acetamide
339. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide
- 10 340. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-dichlorophenyl)acetamide
341. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-difluorophenyl)acetamide
- 15 342. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide
343. 2-(2,3-dihydro-1H-inden-5-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
344. N-(5-isopropyl-1,3-thiazol-2-yl)-1-phenylcyclopropanecarboxamide
- 20 345. 2-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
346. 2-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
- 25 347. N-(5-isopropyl-1,3-thiazol-2-yl)-2,2-diphenylacetamide
348. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-nitrophenoxy)acetamide
349. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)propanamide
- 30 350. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl)propanamide
351. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-isobutylphenyl)propanamide
352. N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxo-2-phenylacetamide
- 35 353. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-phenylpentanamide


354. (E, Z)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-2-butenamide
355. N-(5-isopropyl-1,3-thiazol-2-yl)bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide
- 5 356. N-(5-isopropyl-1,3-thiazol-2-yl)-3-oxo-1-indanecarboxamide
357. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl)butanamide
358. tert-butyl (1S)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-1-methyl-2-oxoethylcarbamate
- 10 359. tert-butyl (1S,2S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-methylbutylcarbamate
360. tert-butyl 2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
361. tert-butyl (1S)-5-amino-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}pentylcarbamate
- 15 362. tert-butyl 4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}butylcarbamate
- 20 363. tert-butyl 1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-3-(tritylamino)propylcarbamate
364. tert-butyl (1S)-1-(benzyloxymethyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
365. tert-butyl (1S)-1-benzyl-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
- 25 366. tert-butyl (1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-(benzylthiomethyl)ethylcarbamate
367. benzyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-[(5-isopropyl-1,3-thiazol-2-yl)amino]-4-oxobutanoate
- 30 368. tert-butyl (2S)-2-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-1-pyrrolidinecarboxylate
369. tert-butyl (1S)-1-(1H-indol-3-ylmethyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
370. tert-butyl (1S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-3-(methylsulfonyl)propylcarbamate
- 35 371. tert-butyl (1S)-2-benzyloxy-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}propylcarbamate

372. tert-butyl (1S)-1-(4-benzyloxybenzyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
373. tert-butyl (1S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-methylpropylcarbamate
5 374. tert-butyl (1S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-3-methylbutylcarbamate
375. benzyl (4S)-4-[(tert-butoxycarbonyl)amino]-5-[(5-isopropyl-1,3-thiazol-2-yl)amino]-5-oxopentanoate
and the pharmaceutically acceptable salts thereof.

10

The compounds of formula (I) of the present invention and the salts thereof can be obtained, for instance, by a process comprising reacting a compound of formula (II)

15



with a compound of formula (III)



20



wherein R and R₁ are as defined above and X is hydroxy or a suitable leaving group;

and, if desired, converting a 2-amino-1,3-thiazole derivative of formula (I) into another such derivative of
25 formula (I), and/or into a salt thereof.

THIS PAGE IS INTENTIONALLY BLANK

THE NEXT PAGE IS PAGE 34

5



Examples of specific compounds of formula (III) wherein X is a suitable leaving group are those wherein X represents a halogen atom, preferably chlorine or bromine.

5 It is clear to the man skilled in the art that if the compound of formula (I), prepared according to the above process is obtained as an admixture of isomers, its separation into the single isomers according to conventional techniques is still within the scope of the
10 present invention.

Likewise, the conversion into the free compound (I) of a corresponding salt thereof, according to well-known procedures in the art, is still within the scope of the invention.

15

The above process is an analogy process which can be carried out according to well known methods.

The reaction between a compound of formula (II) and a carboxylic acid of formula (III) wherein X is a hydroxy
20 group, can be carried out in the presence of a coupling agent or a polymer supported coupling agent such as, for instance, carbodiimide, i.e. 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, or N-Cyclohexylcarbodiimide N'-
25 methylpolystyrene in a suitable solvent such as, for instance, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, 1,4-dioxane, acetonitrile, toluene, or N,N-dimethylformamide at a temperature ranging from about -10°C to reflux for a suitable time, i.e. from about 30 min. to
30 about 96 hours.

The reaction between a compound of formula (II) and a compound of formula (III) can be also carried out, for example, by a mixed anhydride method, using an alkyl chloroformate, such as ethyl, iso-butyl, or iso-propyl
35 chloroformate, in the presence of a tertiary base, such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as, for instance, toluene, dichloromethane, chloroform, tetrahydrofuran, acetonitrile,

diethyl ether, 1,4-dioxane, or N,N-dimethylformamide, at a temperature ranging from about -30°C to room temperature.

The reaction between a compound of formula (II) and a carboxylic acid derivative of formula (III) wherein X is a
5 suitable leaving group can be carried out in the presence of a tertiary base, such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent, such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, acetonitrile, or N,N-
10 dimethylformamide, at a temperature ranging from about -10°C to reflux.

Also the optional conversion of a compound of formula (I) into another compound of formula (I) can be carried out
15 according to known methods.

As an example, the nitro group of a compound of formula (I) may be converted into an amino group by treatment, for example, with stannous chloride in concentrated hydrochloric acid and by using, if necessary, an organic
20 solvent such as acetic acid, 1,4-dioxane and tetrahydrofuran, at a temperature varying between room temperature and about 100°C.

Likewise, an alkylthio or an arylthio group may be converted into the corresponding alkylsulfonyl and
25 arylsulfonyl group by reaction, for example, with m-chloroperbenzoic acid in a suitable solvent such as dichloromethane or chloroform, at a temperature varying between about -5°C and room temperature.

The optional salification of a compound of formula (I) or
30 the conversion of a salt into the free compound as well as the separation of a mixture of isomers into the single isomers may be carried out by conventional methods.

The compounds of formula (II) and (III) according to the
35 process object of the present invention are known compounds or can be obtained according to known methods.

For example, a compound of formula (II) wherein R is as defined above can be obtained by reacting a compound of formula (IV)



- 5 wherein Z is a bromine or chlorine atom, with thiourea in a suitable solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane or toluene, at a temperature varying between room temperature and reflux, for a suitable time ranging from about 1 hour to about 24 hours.
- 10 A compound of formula (III) wherein X is a leaving group as defined above can be obtained according to conventional techniques from the corresponding carboxylic acids of formula (III) wherein X is hydroxy.
- When preparing the compounds of formula (I) according to
- 15 the process object of the present invention, optional functional groups within both the starting materials or the intermediates thereof, which could give rise to unwanted side reactions, need to be properly protected according to conventional techniques.
- 20 Likewise, the conversion of these latter into the free deprotected compounds may be carried out according to known procedures.

Pharmacology

- 25 The compounds of formula (I) are active as cdk/cyclin inhibitors as they gave positive results when tested according to the following procedure.

The inhibiting activity of putative cdk/cyclin inhibitors

30 and the potency of selected compounds was determined through a method of assay based on the use of the MultiScreen-PH 96 well plate (Millipore), in which a phosphocellulose filter paper was placed at each well bottom allowing binding of positive charged substrate after

35 a washing/filtration step.

When a radioactivity labelled phosphate moiety was transferred by the ser/threo kinase to the filter-bound histone, light emitted was measured in a scintillation counter.

- 5 The inhibition assay of cdk2/Cyclin A activity was performed according to the following protocol:

Kinase reaction: 1.5 μ M histone H1 substrate, 25 μ M ATP (0.5 μ Ci $P^{33}\gamma$ -ATP), 30 ng Cyclin A/cdk2 complex, 10 μ M
10 inhibitor in a final volume of 100 μ l buffer (TRIS HCl 10 mM pH 7.5, MgCl₂ 10 mM, 7.5 mM DTT) were added to each well of a 96 U bottom well plate. After 10 min at 37 °C incubation, reaction was stopped by 20 μ l EDTA 120 mM.

15 **Capture:** 100 μ l were transferred from each well to MultiScreen plate, to allow substrate binding to phosphocellulose filter. Plates were then washed 3 times with 150 μ l/well PBS Ca⁺⁺/Mg⁺⁺ free and filtered by MultiScreen filtration system.

20 **Detection:** filters were allowed to dry at 37°C, then 100 μ l/well scintillant were added and ^{33} P labelled histone H1 was detected by radioactivity counting in the Top-Count instrument.

25 **Results:** data were analysed and expressed as % inhibition referred to total activity of enzyme (=100%). All compounds showing inhibition $\geq$ 50 % were further analysed in order to study and define potency (IC₅₀) as
30 well as the kinetic-profile of inhibitor through Ki calculation.

IC₅₀ determination: the protocol used was the same described above, where inhibitors were tested at concentrations ranging from 0.0045 to 10 μ M. Experimental
35 data were analyzed by the computer program GraphPad Prism.

Ki calculation: either the concentration of ATP and histone H1 substrate were varied: 4, 8, 12, 24, 48 μM for ATP (containing proportionally diluted $\text{P}^{33}\gamma\text{-ATP}$) and 0.4, 0.8, 1.2, 2.4, 4.8 μM for histone were used in absence and
 5 presence of two different, properly chosen inhibitor concentrations.

Experimental data were analysed by the computer program SigmaPlot for Ki determination, using a random bireactant system equation:

$$v = \frac{V_{\max} \frac{(A)(B)}{aK_a K_b}}{1 + \frac{(A)}{K_a} + \frac{(B)}{K_b} + \frac{(A)(B)}{aK_a K_b}}$$

15 where A=ATP and B=histone H1.

Following the method above described, a representative compound of formula (I) of the invention, which is 2-[4-(dimethylamino)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide, showed an inhibiting activity towards the
 20 cdk2/cyclin A complex corresponding to 0.1 μM (K_i).

In addition, the inhibiting activity of putative cdk/cyclin inhibitors and the potency of selected compounds was
 25 determined through a method of assay based on the use of a SPA (Scintillation Proximity Assay) 96 well plate assay. The assay is based on the ability of streptavidin coated SPA beads to capture a biotinylated peptide derived from a phosphorylation site of histone.

30 When a radioactivity labelled phosphate moiety was transferred by the ser/threo kinase to the biotinylated histone peptide, light emitted was measured in a scintillation counter.

The inhibition assay of cdk5/p25 activity was performed
 35 according to the following protocol:

Kinase reaction: 1.0 μ M biotinylated histone peptide substrate, 0.25 uCi P33g-ATP, 4 nM cdk2/p25 complex, 0-100 μ M inhibitor in a final volume of 100 μ l buffer (Hepes 20 mM pH 7.5, MgCl₂ 15 mM, 1 mM DTT) were added to each well
5 of a 96 U bottom well plate. After 20 min at 37 °C incubation, the reaction was stopped by the addition of 500 ug SPA beads in phosphate-buffered saline containing 0.1% Triton X-100, 50 uM ATP and 5 mM EDTA. The beads were allowed to settle, and the radioactivity incorporated in
10 the ³³P-labelled peptide was detected in a Top Count scintillation counter.

Results: Data were analyzed and expressed as % Inhibition using the formula:

15
$$100 \times (1 - (\text{Unknown} - \text{Bkgd}) / (\text{Enz. Control} - \text{Bkgd}))$$

IC₅₀ values were calculated using a variation of the four parameter logistics equation:

$$Y = 100 / [1 + 10^{((\text{LogEC}_{50} - X) \times \text{Slope})}]$$

20

Where X = log(uM) and Y = % Inhibition.

The compounds of formula (I) are therefore useful to restrict the unregulated proliferation of tumor cells,
25 hence in therapy in the treatment of various tumors such as, for instance, carcinomas, e.g. mammary carcinoma, lung carcinoma, bladder carcinoma, colon carcinoma, ovary and endometrial tumors, sarcomas, e.g. soft tissue and bone sarcomas, and the hematological malignancies such as, e.g.,
30 leukemias.

In addition, the compounds of formula (I) are also useful in the treatment of other cell proliferative disorders such as psoriasis, vascular smooth cell proliferation associated with atherosclerosis and post-surgical stenosis and
35 restenosis and in the treatment of Alzheimer's disease.

The compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents.

As an example, the above compounds can be administered in combination with one or more chemotherapeutic agents such as, for instance, taxane, taxane derivatives, CPT-11, camptothecin derivatives, anthracycline glycosides, e.g. doxorubicin or epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin and the like, optionally within liposomal formulations thereof.

The compounds of formula (I) of the present invention, suitable for administration to a mammal, e.g. to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and the administration route.

For example, a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mg pro dose, from 1 to 5 times daily.

The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous and/or intrathecal and/or intraspinal injection or infusion.

The present invention also includes pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatine, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

The liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions.

The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.

The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa

butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

The following examples illustrate but do not limit the present invention.

Example 1

Preparation of Ethyl 3-[(5-bromo-1,3-thiazol-2-yl)amino]-3-oxopropanoate

10 Ethyl malonyl chloride (0.88 ml; 6.99 mmol) was added to a mixture of 2-amino-5-bromothiazole hydrobromide (1.30 g; 5.00 mmol) and Et₃N (2.08 ml; 14.94 mmol) in THF (6 ml) at 0-5°C. The mixture was stirred at room temperature overnight, then the reaction was quenched with potassium
15 sarcosinate (0.25 g; 2.00 mmol) and water (12 ml). The product was isolated by filtration as a white solid (0.75 g, 51%): m.p. 165-166°C.

¹H-NMR (CDCl₃) δ ppm: 10.80 (bs, 1H, CONH); 7.38 (s, 1H, thiazole CH); 4.28 (q, J = 7.3 Hz, 2H, COOCH₂CH₃); 3.56 (s, 2H, COCH₂CO); 1.32 (t, J = 7.3 Hz, 2H, COOCH₂CH₃).

Analogously, the following products can be prepared:

N-(5-bromo-1,3-thiazol-2-yl)-2-phenyl-acetamide

m.p. 206-207°C

¹H-NMR (DMSO-d₆) δ ppm: 3.76 (s, 2H, COCH₂Ph); 7.2-7.3 (m, 5H, Ph); 7.54 (s, 1H, thiazole CH); 12.80 (bs, 1H, CONH);

N-(5-bromo-1,3-thiazol-2-yl)-benzamide

m.p. 126-128°C

¹H-NMR (DMSO-d₆) δ ppm: 12.90 (bs, 1H, CONH); 8.07, 7.93 (m, 2H, o-Ph hydrogens); 7.63 (s, 1H, thiazole CH); 7.62, 7.53, 7.48 (m, 3H, m- and p-Ph hydrogens);

Ethyl 4-[(5-bromo-1,3-thiazol-2-yl)amino]-4-oxobutanoate.

Example 2

Preparation of N-(5-Bromo-thiazol-2-yl)-3-hydroxy-propionamide

A mixture of LiBH₄ (44 mg, 2.02 mmol), ethyl 3-[(5-bromo-1,3-thiazol-2-yl)amino]-3-oxopropanoate (340 mg, 1.16 mmol), methanol (0.082 ml, 2.02 mmol), and Et₂O (50 ml) was refluxed for 20 min. The reaction was quenched with 1 N hydrochloric acid with ice-cooling.

The mixture was then diluted with water and extracted with dichloromethane. The extract was dried and the solvent was evaporated under reduced pressure. Purification by silica gel chromatography (dichloromethane/methanol=98:2 and then 95:5) yielded the title compound as a white solid (0.17 g; 52%).

m.p. 182-184°C (dec.)

¹H-NMR (CDCl₃) δ ppm: 10.20 (bs, 1H, CONH); 7.35 (s, 1H, thiazole CH); 4.04 (t, J = 5.4 Hz, 2H, COCH₂CH₂OH); 2.74 (t, J = 5.4 Hz, 2H, COCH₂CH₂OH).

Analogously, starting from the corresponding ester derivative the following product can be prepared:

N-(5-Bromo-1,3-thiazol-2-yl)-4-hydroxybutanamide.

Example 3

Preparation of N-(5-Bromo-thiazol-2-yl)-2-ethoxy-acetamide

EDCI (0.53 g, 2.78 mmol) was added to a solution of ethoxyacetic acid (0.29 g, 2.78 mmol) in CH₂Cl₂ (5 ml) under ice-cooling.

After stirring for 1 h, a solution of 2-amino-5-bromothiazole hydrobromide (0.60 g, 2.31 mmol) and diisopropylethylamine (0.40 ml, 2.34 mmol) in CH₂Cl₂ (5 ml) was added dropwise, and the entire mixture was kept at 0°C for 1 h, then at room temperature overnight.

The solution was evaporated and the residue partitioned between ethyl acetate and water. The ethyl acetate layer was further washed with water, 5% citric acid, water, saturated sodium bicarbonate, and water.

Drying over sodium sulfate and evaporation gave a solid which was triturated with isopropyl ether to give the title compound as a beige solid (0.43 g; 70%)

m.p. 100-102°C

¹H-NMR (CDCl₃) δ ppm: 9.64 (bs, 1H, CONH); 7.38 (s, 1H, thiazole CH); 4.16 (s, 2H, COCH₂O); 3.65 (q, J = 6.8 Hz, 2H, OCH₂CH₃); 1.29 (t, J = 6.8 Hz, 3H, OCH₂CH₃).

5 Analogously, the following products can be prepared:

tert-butyl 3-[(5-bromo-1,3-thiazol-2-yl)amino]-3-oxopropylcarbamate;

Benzyl 4-[(5-bromo-1,3-thiazol-2-yl)amino]-4-oxobutylcarbamate;

10 tert-butyl 4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}phenylcarbamate

tert-butyl 4-[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}phenylcarbamate

15 tert-butyl 4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}-1,3-thiazol-2-ylcarbamate;

N-(5-bromo-1,3-thiazol-2-yl)-2-bromoacetamide;

N-(5-isopropyl-1,3-thiazol-2-yl)-2-bromoacetamide;

2-N-[2-(3-pyridyl)-acetyl-amino]-5-bromo-thiazole

m.p. 232-235°C

20 ¹H-NMR (DMSO-d₆): 3.82 (s, 2H, COCH₂Ph); 7.34 (dd, J=4.4, 7.7 Hz, 1H, H5 Py); 7.55 (s, 1H, thiazole CH); 7.71 (ddd, J=1.6, 2.2, 7.7 Hz, 1H, H4 Py); 8.45 (dd, J=1.6, 4.9 Hz, 1H, H6 Py); 8.49 (d, J=2.2 Hz, 1H, H2 Py); 12.65 (s, 1H, CONH);

25 2-N-[2-(3-pyridyl)-acetyl-amino]-5-isopropyl-thiazole

m.p. 178-180°C (dec.)

¹H-NMR (DMSO-d₆) δ ppm: 12.20 (bs, 1H, CONH); 8.45, 7.7, 7.35 (m, 4H, Py); 7.17 (s, 1H, thiazole CH); 3.78 (s, 2H, COCH₂); 3.14 (m, 1H, CH(Me)₂); 1.22 (d, 6H, CHMe₂);

30 N-(5-bromo-1,3-thiazol-2-yl)-2-(3-hydroxyphenyl)acetamide;

N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-hydroxyphenyl)acetamide

m.p. 206-208°C.

¹H-NMR (DMSO-d₆) δ ppm: 12.1 (bs, 1H, CONH); 9.34 (s, 1H, OH); 7.14 (s, 1H, thiazole CH); 7.1 (t, 1H, H5 Ph); 6.6-6.7

35

(m, 3H, H2, H4, H6 Ph); 3.6 (s, 2H, COCH₂); 3.08 (ept, 1H, CHMe₂); 1.22 (d, 6H, CHMe₂);

N-(5-bromo-1,3-thiazol-2-yl)-2-(3-methoxyphenyl)acetamide;

N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-

5 methoxyphenyl)acetamide

m.p. 97-98°C.

¹H-NMR (DMSO-d₆) δ ppm: 12.12 (s, 1H, CONH); 7.21 (dd, 1H, H5

Ph); 7.14 (d, 1H, thiazole CH); 6.87 (m, 2H, H2, H6 Ph);

6.81 (ddd, 1H, H4 Ph); 3.72 (s, 3H, OMe); 3.67 (s, 2H,

10 COCH₂); 3.07 (m, 1H, CHMe₂); 1.22 (d, 6H, CHMe₂);

N-(5-bromo-1,3-thiazol-2-yl)-2-(3-chlorophenyl)acetamide;

N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-chlorophenyl)acetamide

m.p. 116-118°C.

¹H-NMR (CDCl₃) δ ppm: 11.8 (bs, 1H, CONH); 7.32 (s, 1H, H2

15 Ph); 7.24 (m, 3H, H4, H5, H6 Ph); 7.04 (s, 1H, thiazole

CH); 3.76 (s, 2H, COCH₂); 3.13 (m, 1H, CHMe₂); 1.31 (d, 6H,

CHMe₂);

N-(5-bromo-1,3-thiazol-2-yl)-2-(4-hydroxyphenyl)acetamide;

N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-

20 hydroxyphenyl)acetamide

¹H-NMR (DMSO-d₆) δ ppm: 12.07 (bs, 1H, CONH); 9.33 (sb, 1H,

OH); 7.17-6.7 (m, 5H, Ar+ CHthiazole); 3.60 (s, 2H, COCH₂);

3.1 (m, 1H, CHMe₂); 1.23 (d, 6H, CHMe₂);

N-(5-bromo-1,3-thiazol-2-yl)-2-(3,4-

25 dihydroxyphenyl)acetamide;

N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-

dihydroxyphenyl)acetamide

m.p. 168-169°C.

¹H-NMR (DMSO-d₆) δ ppm: 12.01 (bs, 1H, CONH); 8.79 (sb, 2H, 2

30 OH); 7.12 (s, 1H, thiazole CH); 6.69 (d, 1H, H2 Ph); 6.63

(d, 1H, H5 Ph); 6.52 (dd, 1H, H6 Ph); 3.48 (s, 2H, COCH₂);

3.06 (m, 1H, CHMe₂); 1.22 (d, 6H, CHMe₂);

N-(5-bromo-1,3-thiazol-2-yl)-2-(4-hydroxy-3-

methoxyphenyl)acetamide;

35 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-hydroxy-3-

methoxyphenyl)acetamide

m.p. 115-116°C.

¹H-NMR (DMSO-d₆) δ ppm: 12.0 (bs, 1H, CONH); 8.80 (s, 1H, OH); 7.12 (d, 1H, thiazole CH); 6.88 (s, 1H, H₂ Ph); 6.68 (m, 2H, H₅, H₆ Ph); 3.73 (s, 3H, OMe); 3.56 (s, 2H, COCH₂); 3.07 (m, 1H, CHMe₂); 1.22 (d, 6H, CHMe₂);

- 5 N-(5-bromo-1,3-thiazol-2-yl)-2-(4-methoxyphenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methoxyphenyl)acetamide
m.p. 129-130°C.

- 10 ¹H-NMR (DMSO-d₆) δ ppm: 12.08 (s, 1H, CONH); 7.21 (dd, 2H, H₂, H₆ Ph); 7.13 (d, 1H, thiazole CH); 6.87 (dd, 2H, H₃, H₅ Ph); 3.70 (s, 3H, OMe); 3.62 (s, 2H, COCH₂); 3.06 (m, 1H, CHMe₂); 1.22 (d, 6H, CHMe₂);
N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-acetamide
m.p. 135-137°C

- 15 ¹H-NMR (DMSO-d₆) δ ppm: 12.20 (bs, 1H, CONH); 7.29 (m, 5H, Ph); 7.13 (s, 1H, thiazole CH); 3.70 (s, 2H, COCH₂); 3.07 (m, 1H, CHMe₂); 1.22 (d, 6H, CHMe₂);
2-[3-(3-chloropropoxy)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
20 m.p. 91-92°C

- ¹H-NMR (DMSO-d₆) δ ppm: 12.08 (bs, 1H, CONH); 7.21 (t, 1H, H₅ Ph); 7.13 (s, 1H, thiazole CH); 6.8-6.9 (m, 3H, H₂, H₄, H₆ Ph); 4.05 (t, 2H, OCH₂CH₂CH₂Cl); 3.77 (t, 2H, OCH₂CH₂CH₂Cl); 3.67 (s, 2H, COCH₂); 3.07 (ept, 1H, CHMe₂); 2.14 (quint, 2H, OCH₂CH₂CH₂Cl); 1.22 (d, 6H, CHMe₂); and
25 2-[3-(2-chloroethoxy)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
m.p. 134-135°C

- ¹H-NMR (DMSO-d₆) δ ppm: 12.09 (bs, 1H, CONH); 7.22 (t, 1H, H₅ Ph); 7.13 (s, 1H, thiazole CH); 6.8-6.9 (m, 3H, H₂, H₄, H₆ Ph); 4.2 (t, 2H, OCH₂CH₂Cl); 3.91 (t, 2H, OCH₂CH₂Cl); 3.67 (s, 2H, COCH₂); 3.07 (ept, 1H, CHMe₂); 1.22 (d, 6H, CHMe₂).

Example 4

- 35 Preparation of N-(5-bromo-thiazol-2-yl)-4-sulfamoyl-benzamide.

To a mixture of 4-sulfamoylbenzoic acid (1.0 g, 4.97 mmol), Et₃N (1.5 ml, 10.78 mmol), DMF (5 ml) and THF (5 ml) isobutyl chloroformate (0.70 ml, 5.36 mmol) was added dropwise at -10°C.

- 5 After stirring for 1 h, a solution of 2-amino-5-bromothiazole hydrobromide (1.55 g, 5.96 mmol) and Et₃N (0.83 ml, 5.96 mmol) in DMF (6 ml) and THF (4 ml) was added dropwise to the mixture at the same temperature.

The resulting mixture was gradually warmed to room
10 temperature over a period of 3 h and then concentrated by evaporation of the solvent in vacuo. To the resultant residue AcOEt and 5% aqueous NaHCO₃ were added. The separated organic phase was washed with water, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure.

- 15 The residual solid was purified by flash chromatography (dichloromethane/methanol/30% aqueous ammonia=95:5:0.5) to afford the title compound as a yellow solid (0.77 g, 43%)
m.p. 268-270°C

¹H-NMR (DMSO-d₆) δ ppm: 7.54 (s, 2H, SO₂NH₂); 7.67 (s, 1H, thiazole CH); 7.94 (d, J=8.8 Hz, 2H, H₃ and H₅ Ph); 8.21 (d, J=8.8 Hz, 2H, H₂ and H₆ Ph); 13.10 (bs, 1H, CONH).

Analogously, the following product can be prepared:

N-(5-isopropyl-thiazol-2-yl)-4-sulfamoyl-benzamide

m.p. 222-224°C.

- 25 ¹H-NMR (DMSO-d₆) δ ppm: 12.65 (bs, 1H, CONH); 8.18 (dd, 2H, H₂, H₆ Ph); 7.92 (dd, 2H, H₃, H₅ Ph); 7.51 (s, 2H, SO₂NH₂); 7.25 (s, 1H, thiazole CH); 3.13 (m, 1H, CHMe₂); 1.28 (d, 6H, CHMe₂).

30 **Example 5**

Preparation of 4-amino-N-(5-bromo-1,3-thiazol-2-yl)butanamide hydrobromide

- A solution (1.3 ml) of hydrogen bromide in glacial acetic acid (33%) was added to benzyl 4-[(5-bromo-1,3-thiazol-2-yl)amino]-3-oxobutylcarbamate (0.72 g, 1.81 mmol) and the
35 mixture was stirred at room temperature for 1 h.

Ether was added and the solid was filtered and washed with ether. The crude product was recrystallized from MeOH/ether to afford the title compound as a beige solid (0.38 g, 61%), m.p. 211-213°C (dec.)

- 5 ¹H-NMR (DMSO-d₆) δ ppm: 1.84 (m, 2H, COCH₂CH₂CH₂NH₂); 2.53 (t, J=6.8 Hz, 2H, COCH₂CH₂CH₂NH₂); 2.81 (m, 2H, COCH₂CH₂CH₂NH₂); 7.68 (bs, 3H, NH₃⁺); 12.42 (s, 1H, CONH).

Example 6

10 Preparation of 3-amino-N-(5-bromo-1,3-thiazol-2-yl)propionamide hydrochloride

A solution 3.6 N HCl in isopropanol (14 ml) was added to tert-butyl 3-[(5-bromo-1,3-thiazol-2-yl)amino]-4-oxopropylcarbamate (0.90 g, 2.57 mmol) and the mixture was
15 stirred at room temperature overnight. The solvent was evaporated and the residual solid was triturated in ether, filtered and dried in vacuo to afford the title compound as a white solid (0.73 g, quantitative yield)
m.p. 255°C ca. (dec.)

- 20 ¹H-NMR (DMSO-d₆) δ ppm: 2.83 (t, J=6.8 Hz, 2H, COCH₂CH₂NH₂); 3.07 (q, J=6.4 Hz, 2H, COCH₂CH₂NH₂); 7.55 (s, 1H, thiazole CH); 7.96 (bs, 3H, NH₃⁺); 12.58 (s, 1H, CONH).

Analogously, the following compounds can be prepared:

- 25 2-(4-aminophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
¹H-NMR (DMSO-d₆) δ ppm: 1.22 (d, 6H, CHMe₂); 3.07 (m, 1H, CHMe₂); 3.47 (s, 2H, COCH₂); 4.94 (s, 2H, NH₂); 6.48 (m, 2H, H₃, H₅ Ph); 6.93 (m, 2H, H₂, H₆ Ph); 7.12 (d, 1H, CH thiazole); 12.00 (s, 1H, CONH).

- 30 4-amino-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide

¹H-NMR (DMSO-d₆) δ ppm: 1.29 (d, 6H, CHMe₂); 3.12 (m, 1H, CHMe₂); 6.58 (m, 2H, H₃, H₅ Ph); 7.18 (d, 1H, CH thiazole); 7.82 (m, 2H, H₂, H₆ Ph); 12.80 (bs, 1H, CONH).

- 35 2-(2-amino-1,3-thiazol-4-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide

m.p. 204-206°C ca. (dec.)

¹H-NMR (DMSO-d₆) δ ppm: 1.24 (d, 6H, CHMe₂); 3.10 (m, 1H, CHMe₂); 3.54 (s, 2H, COCH₂); 6.30 (s, 1H, H5 thiazole); 6.88 (s, 2H, NH₂); 7.13 (s, 1H, H4 thiazole); 11.90 (s, 1H, CONH).

5

Example 7**Preparation of N-(5-isopropyl-1,3-thiazol-2-yl)-butanamide**

Triethylamine (0.97 ml; 6.34 mmol) and butanoyl chloride (0.52 ml; 5.07 mmol) were added in this order to a solution of 2-amino-5-isopropyl-1,3-thiazole (0.6 g; 4.23 mmol) in dichloromethane (8 ml), cooled to -5°C.

The reaction mixture was stirred at -5°C for 2 hours and then warmed to room temperature. After additional 4 hours, the organic layer was washed with water, saturated sodium bicarbonate, 1N hydrochloric acid, brine, dried over sodium sulfate and evaporated. The residue was recrystallized from cyclohexane to yield 0.45 g (50%) of the title compound as a colourless solid (m.p. 95-97°C)

¹H-NMR (DMSO-d₆) δ ppm: 11.82 (s, 1H, CONH); 7.11 (s, 1H, thiazole CH); 3.08 (m, 1H, CHMe₂); 2.34 (t, J = 7.1 Hz, 2H, COCH₂CH₂CH₃); 1.58 (m, 2H, COCH₂CH₂CH₃); 1.23 (d, J = 6.6 Hz, 6H, (CH₃)₂CH); 0.87 (t, J = 7.1 Hz, 3H, COCH₂CH₂CH₃).

Analogously, the following compounds can be prepared:

25 N-(5-bromo-1,3-thiazol-2-yl)-butanamide

m.p. 163-164°C

¹H-NMR (DMSO-d₆) δ ppm: 12.27 (bs, 1H, CONH); 7.50 (s, 1H, thiazole CH); 2.39 (t, 2H, COCH₂CH₂CH₃); 1.59 (m, 2H, COCH₂CH₂CH₃); 0.87 (t, 3H, COCH₂CH₂CH₃);

30 N-(5-chloro-1,3-thiazol-2-yl)-butanamide

m.p. 170-171°C

¹H-NMR (DMSO-d₆) δ ppm: 12.25 (bs, 1H, CONH); 7.46 (s, 1H, thiazole CH); 2.38 (t, 2H, COCH₂CH₂CH₃); 1.59 (m, 2H, COCH₂CH₂CH₃); 0.87 (t, 3H, COCH₂CH₂CH₃);

35 N-(5-phenyl-1,3-thiazol-2-yl)-butanamide

m.p. 183-184°C

¹H-NMR (DMSO-d₆) δ ppm: 12.13 (s, 1H, CONH), 7.84 (s, 1H, thiazole CH); 7.58 (d, J = 6.8 Hz, 2H, o-Ph hydrogens); 7.39 (dd, J = 6.8 and 7.8 Hz, 2H, m-Ph hydrogens); 7.28 (t, J = 7.8 Hz, 1H, p-Ph hydrogens); 2.41 (t, J = 7.3 Hz, 2H, COCH₂CH₂CH₃); 1.61 (m, 2H, COCH₂CH₂CH₃); 0.89 (t, J = 7.3 Hz, 3H, COCH₂CH₂CH₃);

N-(5-nitro-1,3-thiazol-2-yl)-butanamide

m.p. 175-176°C

¹H-NMR (DMSO-d₆) δ ppm: 13.02 (s, 1H, CONH); 8.60 (s, 1H, thiazole CH); 2.48 (t, J = 7.3 Hz, 2H, COCH₂CH₂CH₃); 1.62 (m, 2H, COCH₂CH₂CH₃); 0.89 (t, J = 7.3 Hz, 3H, COCH₂CH₂CH₃);

N-(5-methyl-1,3-thiazol-2-yl)-butanamide

m.p. 137-138°C

¹H-NMR (CDCl₃) δ ppm: 11.89 (s, 1H, CONH); 7.04 (s, 1H, thiazole CH); 2.48 (t, J = 7.3 Hz, 2H, COCH₂CH₂CH₃); 2.41 (s, 3H, CH₃); 1.80 (m, 2H, COCH₂CH₂CH₃); 1.02 (t, J = 7.3 Hz, 3H, COCH₂CH₂CH₃);

N-(5-benzyl-1,3-thiazol-2-yl)-butanamide

m.p. 147-149°C

¹H-NMR (CDCl₃) δ ppm: 7.23 (m, 5H, Ph); 7.07 (s, 1H, thiazole CH); 4.08 (s, 2H, CH₂Ph); 2.45 (t, J = 7.8 Hz, 2H, COCH₂CH₂CH₃); 1.76 (m, 2H, COCH₂CH₂CH₃); 0.97 (t, J = 7.8 Hz, 2H, COCH₂CH₂CH₃);

N-(5-isobutyl-1,3-thiazol-2-yl)-butanamide

m.p. 58-60°C

¹H-NMR (CDCl₃) δ ppm: 7.03 (s, 1H, thiazole CH); 2.61 (d, J = 7.3 Hz, 2H, Me₂CHCH₂); 2.45 (t, J = 7.8 Hz, 2H, COCH₂CH₂CH₃); 1.81 (m, 1H, Me₂CHCH₂); 1.78 (m, 2H, COCH₂CH₂CH₃); 1.01 (t, J = 7.8 Hz, 3H, COCH₂CH₂CH₃); 0.95, 0.93 (s, 6H, Me₂CHCH₂);

N-(5-cyclopropyl-1,3-thiazol-2-yl)-butanamide;

N-{5-[2-(methylsulfonyl)ethyl]-1,3-thiazol-2-yl}-butanamide

m.p. 153-155°C

¹H-NMR (CDCl₃) δ ppm: 11.01 (s, 1H, CONH); 7.21 (s, 1H, thiazole CH); 3.34 (m, 4H, CH₃SO₂CH₂CH₂); 2.90 (s, 3H,

CH₃SO₂); 2.48 (t, J = 7.3 Hz, 2H, COCH₂CH₂CH₃); 1.80 (m, 2H, COCH₂CH₂CH₃); 1.02 (t, J = 7.3 Hz, 3H, COCH₂CH₂CH₃);

N-[5-(2-methylthioethyl)-1,3-thiazol-2-yl]-butanamide

m.p. 67-69°C

5 ¹H-NMR (CDCl₃) δ ppm: 11.63 (bs, 1H, NHCO), 7.26 (s, 1H, thiazole CH), 3.06 (t, J = 7.0 Hz, 2H, CH₃SCH₂CH₂); 2.77 (t, J = 7.0 Hz, 2H, CH₃SCH₂CH₂); 2.48 (t, J = 7.3 Hz, 2H, COCH₂CH₂CH₃); 2.14 (s, 3H, CH₃S); 1.80 (m, 2H, COCH₂CH₂CH₃); 1.02 (t, J = 7.3 Hz, 3H, COCH₂CH₂CH₃);

10 N-{5-[2-(methoxycarbonyl)ethyl]-1,3-thiazol-2-yl}-butanamide;

N-[5-(3-methoxy-propyl)-1,3-thiazol-2-yl]-butanamide

m.p. 80-82°C

15 ¹H-NMR (CDCl₃) δ ppm: 11 (sb, 1H, NHCO); 7.07 (s, 1H, H4 thiazole); 3.41 (t, 2H, CH₂CH₂CH₂OMe); 3.34 (s 3H, OCH₃); 2.85 (t, 2H, CH₂CH₂CH₂OMe); 2.46 (t, 2H, NHCOCH₂); 1.91 (m, 2H, CH₂CH₂CH₂OMe); 1.80 (t, 2H, NHCOCH₂CH₂CH₃); 1.01 (t, 3H, NHCOCH₂CH₂CH₃);

N-[5-(2-ethoxy-ethyl)-1,3-thiazol-2-yl]-butanamide

20 m.p. 74-76°C

¹H-NMR (CDCl₃) δ ppm: 7.14 (s, 1H, H4 thiazole); 3.64 (t, 2H, CH₂CH₂OEt); 3.52 (q 2H, OCH₂CH₃); 3.02 (t, 2H, CH₂CH₂OEt); 2.47 (t, 2H, NHCOCH₂); 1.80 (m, 2H, NHCOCH₂CH₂); 1.23 (t, 3H, OCH₂CH₃); 1.02 (t, 3H, NHCOCH₂CH₂CH₃);

25 N-[5-(indol-3-yl-methyl)-1,3-thiazol-2-yl]-butanamide

m.p. 240-242°C

30 ¹H-NMR (CDCl₃) δ ppm: 9.95 (bs, 1H, CONH); 8.00 (bs, 1H, NH indole); 7.54 (d, 1H, H4 indole); 7.36 (d, 1H, H7 indole); 7.19 (m, 1H, H6 indole); 7.17 (s, 1H, thiazole CH); 7.09 (m, 1H, H5 indole); 7.07 (s, 1H, H2 indole); 4.23 (s, 2H, CH₂); 2.39 (m 2H, CH₂CO); 1.73 (m, 2H, CH₃CH₂CH₂); 0.96 (t, 3H, CH₃CH₂CH₂).

N-[5-(3-dimethylaminoimino-butyl)-1,3-thiazol-2-yl]-butanamide.

35

Example 8

2-amino-5-isopropyl-1,3-thiazole

2 ml (18.6 mmol) of 3-methylbutyraldehyde were dissolved in 15 ml of dioxane. 40.4 ml (18.6 mmol) of a solution 2 % v/v of bromine in dioxane was dropped therein at 0°C.

5 The mixture was maintained at room temperature under stirring for 2 hours, then 2.83 g (37.2 mmol) of thiourea and 5 ml of ethanol were added.

After 6 hours at room temperature the solution was evaporated to dryness, the residue was dissolved in
10 methylene chloride and the product extracted with 1M hydrochloric acid; the aqueous layer was made basic by using 30% ammonium hydrate and extracted again with methylene chloride. The organic phase was dried over sodium sulfate and evaporated under vacuum. The residue was
15 chromatographed on a silica gel column, eluting with cyclohexane-ethylacetate to give 1.1 g (42% yield) of the title compound.

¹H-NMR (DMSO-d₆) δ ppm: 6.6 (s, 2H, NH₂); 6.58 (s, 1H, thiazole CH); 2.9 (m, 1H, CHMe₂); 1.18 (s, 3H, MeCHMe);
20 1.17 (s, 3H, MeCHMe).

Analogously the following products can be prepared starting from the suitable aldehyde:

2-amino-5-isobutyl-1,3-thiazole

25 ¹H-NMR (DMSO-d₆) δ ppm: 6.61 (sb, 2H, NH₂); 6.56 (s, 1H, thiazole CH); 2.39 (dd, 2H, CH₂CHMe₂); 1.65 (m, 1H, CHMe₂); 0.85 (d, 6H, CHMe₂);

2-amino-5-phenyl-1,3-thiazole;

2-amino-5-benzyl-1,3-thiazole;

30 ¹H-NMR (DMSO-d₆) δ ppm: 7.3-7.2 (m, 5H, Ph); 6.68 (s, 1H, thiazole CH); 6.67 (sb, 2H, NH₂); 3.87 (s, 2H, CH₂Ph);

2-amino-5-(3-indolylmethyl)-1,3-thiazole;

2-amino-5-ethoxyethyl-1,3-thiazole;

2-amino-5-methoxypropyl-1,3-thiazole;

35 2-amino-5-cyclopropyl-1,3-thiazole;

2-amino-5-methylthioethyl-1,3-thiazole;

2-amino-5-formyl-1,3-thiazole;

2-amino-5-(3-dimethylaminoimino)butyl-1,3-thiazole.

Example 9

4-ethoxy-1-butanol

5 85 mg (0.004 mmol) of sodium were dissolved in 50 ml of methanol and 8.7 g (0.23 mol) of sodium borohydride were added. A solution of 4.6 g (0.032 mol) of methyl 4-ethoxybutanoate in 20 ml of methanol was dropped to the mixture under stirring. The reaction is maintained at reflux for 6
10 hours, then 300 ml of brine were added and the product was extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness to give 2.25 g (61% yield) of the title compound.

15 Analogously the following products can be prepared starting from the suitable ester:

2-cyclopropyl-1-ethanol;
3-(3-indolyl)-1-propanol; and
5-dimethylaminoimino-1-hexanol.

20

Example 10

Methyl 3-(3-indolyl)-propanoate

2 g (10.57 mmol) of 3-indolepropionic acid were dissolved
25 in 50 ml of methanol. The solution was cooled to 0°C and 5 ml of sulfuric acid 96% were dropped under stirring. The solution was maintained at room temperature overnight and then poured onto ice-water, basified with 30 % ammonium hydrate and finally extracted with methylene chloride. The
30 organic layer was dried over anhydrous sodium sulfate and evaporated to dryness to give 2.3 g of an oily product (93% yield).

Analogously the following products can be prepared starting
35 from the suitable carboxylic acid:

Methyl 4-ethoxy butanoate;
Methyl cyclopropylacetate; and
5-methoxycarbonyl-ethyl-2-amino-1,3-thiazole.

Example 11**4-methyl-pentanal**

1.24 ml (14.18 mmol) of oxalyl chloride were dissolved in
5 10 ml of methylene chloride and after cooling to -60°C ,
2.31 ml of DMSO (35 mmoles) were dropped.

After 5 minutes at the same temperature, a solution of 1 ml
(11.9 mmol) of 4-methyl-1-pentanol in 10 ml of methylene
chloride was slowly dropped. The mixture was maintained
10 under stirring for 30 minutes at the same temperature, then
8.3 ml (59.5 mmol) of triethylamine were added. After 2
hours at 0°C water was added. The mixture was diluted with
methylene chloride and washed successively with 1M
hydrochloric acid, water, saturated sodium bicarbonate and
15 finally with brine. The organic layer was dried over
anhydrous sodium sulfate and evaporated to dryness to give
0.7 g (25% yield) of the title compound.

Analogously the following products can be prepared starting
from the suitable alcohol:

20 2-cyclopropyl-1-ethanal;
4-methylthio-1-butanal;
4-ethoxy-1-butanal;
5-methoxy-1-pentanal; and
5-dimethylaminoimino-1-hexanal.

25

Example 12**5-benzyloxy-1-methoxy-pentane**

1.6 g (0.039 mol) of 55% sodium hydride in oil were added to
50 ml of dimethylformamide under stirring at room
30 temperature. 5 ml (0.026 mol) of 5-benzyloxy-1-pentanol and
2.43 ml (0.039 mol) of methyl iodide were then added
successively. After a night the excess of sodium hydride
was decomposed with water and the solvent evaporated under
vacuum. The residue was redissolved with methylene
35 chloride and washed with water. The organic layer was
finally dried over anhydrous sodium sulfate and evaporated
to give 3.5 g (70% yield) of the title compound.

Analogously, by using ethyl iodide, the following compound can be prepared:

4-ethoxy-butanoic acid.

5 **Example 13**

5-methoxy-1-pentanol

3.5 g (0.018 mol) of 5-benzyloxy-1-methoxy-pentane were dissolved in 50 ml of ethanol and 400 mg of 10% palladium on activated charcoal were added. The mixture was
10 hydrogenated at 40 psi at room temperature for 5 hours, then filtered on celite and evaporated under vacuum to give 1.77 g (84% yield) of the title compound.

Example 14

15 **Ethyl 5-dimethylaminoimino-hexanoate**

15.8 g (100 mmol) of ethyl 4-acetyl-butanoate and 6 g (100 mmol) of anhydrous N,N-dimethyl hydrazine in 50 ml of toluene containing 0.1 ml of trifluoroacetic acid were heated at 70 °C for 5 hours. The mixture was then washed
20 with water, dried over anhydrous sodium sulfate and evaporated to give 12.3 g (79% yield) of the title compound.

Example 15

25 **N-[5-(3-oxo-butyl)-1,3-thiazol-2-yl]-butanamide**

To a stirred solution of 200 mg (1 mmol) of cupric acetate in 10 ml of water 141 mg (0.5 mmol) of N-[5-(3-dimethylaminoimino-butyl)-1,3-thiazol-2-yl]-butanamide in
30 10 ml of tetrahydrofuran were added. After 2 hours the solvent was removed under reduced pressure, a mixture of aqueous ammonium chloride and ammonium hydroxide was added and the product extracted with methylene chloride to give after drying and concentration 114 mg (95% yield) of the title compound.

35

Example 16

2-benzyloxycarbonylamino-5-formyl-1,3-thiazole

1 g (7.8 mmol) of 2-amino-5-formyl-1,3-thiazole was dissolved in 25 ml of tetrahydrofuran and 1.35 ml (9.36 mmol) of triethylamine and 1.33 ml (9.36 mmol) of benzylchloroformate were added at 0°C under stirring. After 8 hours at room temperature the solvent was evaporated, the residue redissolved with methylene chloride and washed with saturated tartaric acid and then with water. The solvent was dried over anhydrous sodium sulfate and evaporated. The residue was purified by chromatography on silica gel using cyclohexane-ethylacetate as eluent to give 1.3 g (65% yield) of the title compound.

Example 17**5-hydroxymethyl-2-benzyloxycarbonylamino-1,3-thiazole**

530 mg (14 mmol) of sodium borohydride were added in small portions to a stirred solution of 7 g (27 mmol) of 2-benzyloxycarbonylamino-5-formyl-1,3-thiazole in 80 ml of methanol at room temperature. The reaction went on for 2 hours. After evaporation of the solvent the residue was purified by chromatography (cyclohexane-ethylacetate) to give 5.05 g (71% yield) of the title compound.

Example 18**2-benzyloxycarbonylamino-5-(4-phenyl-1-sulfonyloxy)methyl-1,3-thiazole**

To a solution of 1 g (3.78 mmol) of 2-benzyloxycarbonylamino-5-hydroxymethyl-1,3-thiazole in 25 ml of pyridine 0.86 g (4.54 mmol) of tosyl chloride in 10 ml of pyridine were dropped at 0°C. After stirring at room temperature for 6 hours the solvent was evaporated under vacuum, the residue redissolved with methylene chloride, washed with 1M hydrochloric acid and finally with water. The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was purified by chromatography on silica gel (cyclohexane-ethylacetate) to give 1.2 g (80% yield) of the title compound.

Example 19

2-benzyloxycarbonylamino-5-(2-ethoxycarbonyl-3-ethoxycarbonylethyl)-1,3-thiazole

To a suspension of 321 mg of 55% sodium hydride in oil (7.4 mmol) in 20 ml of tetrahydrofuran 1.12 ml (7.4 mmol) of diethylmalonate were added. After 30 minutes, a solution of 1.5 g (3.7 mmol) of 2-benzyloxycarbonylamino-5-(4-phenyl-1-sulphonyloxy)methyl-1,3-thiazole in 10 ml of the same solvent was dropped under stirring. After 6 hours the solvent was evaporated and the residue redissolved with methylene chloride and washed with water. The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was chromatographed on a silica gel column (cyclohexane-ethylacetate) to give 1.05 g (70% yield) of the title compound.

Example 20

2-benzyloxycarbonylamino-5-ethoxycarbonylethyl-1,3-thiazole

To a solution of 4.06 g (10 mmol) of 2-benzyloxycarbonylamino-5-(2-ethoxycarbonyl-3-ethoxycarbonylethyl)-1,3-thiazole in 10 ml of dimethylsulphoxide 0.64 g (11 mmol) of sodium chloride and 0.36 (20 mmol) of water were added under stirring. The mixture was heated at 160 °C for 8 hours and then the solvent removed under vacuum. The residue was redissolved with methylene chloride and washed with brine. After drying and concentration the residue was chromatographed on a silica gel column (cyclohexane-ethylacetate) to give 2.67 g (80% yield) of the title compound.

Example 21

2-amino-5-carboxyethyl-1,3-thiazole

1 g (2.9 mmol) of 2-benzyloxycarbonylamino-5-ethoxycarbonylethyl-1,3-thiazole was dissolved in 20 ml of 33% hydrobromic acid in acetic acid. After 2 hours at room temperature, the solvent was evaporated under vacuum. The residue was redissolved in the minimum amount of water and the hydrobromide of the title compound was precipitated by adding diethylether (75% yield).

Example 22**Preparation of methyl 2-[3-(3-chloropropoxy)phenyl]acetate**

A mixture of methyl (m-hydroxyphenyl)acetate ((5 g, 0.03
5 moles), 1-bromo-3-chloropropane (3.26 ml, 0.03 moles) and
anhydrous potassium carbonate (6.4 g) in anhydrous acetone
(60 ml) was refluxed for 40 hours. After cooling, the
precipitate was filtered off and the solution was
evaporated to dryness to give the product as an oil, which
10 was purified by flash chromatography with hexane:AcOEt
(97:3) as eluent (6.2 g, 85% yield).

Analogously, the following product can be prepared:
methyl 2-[3-(2-chloroethoxy)phenyl]acetate.

15 Example 23**Preparation of 2-[3-(3-chloropropoxy)phenyl]acetic acid**

A mixture of methyl 2-[3-(3-chloropropoxy)phenyl]acetate
(4.95 g, 0.02 moles) and a solution of 1N sodium hydroxide
(0.02 moles) was stirred at room temperature for 24 hours.
20 After acidification the acid separated as white powder
(4.53 g, 97% yield)

m.p. 83-84°C

Analogously, the following product can be prepared:

2-[3-(2-chloroethoxy)phenyl]acetic acid

25 m.p. 100-101°C.

Example 24**Preparation of N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-[3-(4-morpholinyl)propoxy]phenyl]acetamide**

30 A mixture of 2-[3-(3-chloropropoxy)phenyl]-N-(5-isopropyl-
1,3-thiazol-2-yl)acetamide (1.00 g, 2.8 mmoles), morpholine
(1.24 ml, 14.2 mmoles), potassium iodide (0.24 g, 1.4
mmoles) in anhydrous dimethylformamide (3.5 ml) was heated
at 100°C for 6 hours. The solution was acidified and
35 extracted with ether to eliminate unreacted products; then
the solution was basified and extracted with ether. The
solvent was evaporated to dryness to give the product as an
oily semisolid which was purified by flash chromatography

with dichloromethane:methanol (97:3) as eluent (1.0 g, 87% yield)

¹H-NMR (DMSO-d₆) δ ppm: 12.09 (bs, 1H, CONH); 7.21 (t, 1H, H5 Ph); 7.13 (s, 1H, thiazole CH); 6.8-6.9 (m, 3H, H2, H4, H6 Ph); 3.97 (t, 2H, OCH₂CH₂CH₂N); 3.66 (s, 2H, COCH₃); 3.54 (t, 2H, OCH₂CH₂N); 3.07 (ept, 1H, CHMe₂); 2.39 (t, 2H, OCH₂CH₂CH₂N); 2.33 (t, 2H, OCH₂CH₂N); 2.14 (quint, 2H, OCH₂CH₂CH₂N); 1.22 (d, 6H, CHMe₂).

10 Analogously, the following product can be prepared:

N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[2-(4-morpholinyl)ethoxy]phenyl}acetamide

¹H-NMR (DMSO-d₆) δ ppm: 12.11 (bs, 1H, CONH); 7.20 (t, 1H, H5 Ph); 7.13 (d, 1H, thiazole CH); 6.7-6.9 (m, 3H, H2, H4, H6 Ph); 4.04 (t, 2H, OCH₂CH₂N); 3.66 (s, 2H, COCH₃); 3.55 (m, 4H, OCH₂CH₂N morpholine); 3.08 (m, 1H, CHMe₂); 2.66 (t, 2H, OCH₂CH₂N); 2.44 (m, 4H, OCH₂CH₂N morpholine); 1.22 (d, 6H, CHMe₂);

20 N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(1-pirrolidinyl)propoxy]phenyl}acetamide

¹H-NMR (DMSO-d₆) δ ppm: 12.1 (bs, 1H, CONH); 7.19 (t, 1H, H5 Ph); 7.13 (d, 1H, thiazole CH); 6.7-6.9 (m, 3H, H2, H4, H6 Ph); 3.97 (t, 2H, OCH₂CH₂CH₂N); 3.66 (s, 2H, COCH₃); 3.08 (m, 1H, CHMe₂); 2.50 (m, 2H, OCH₂CH₂CH₂N); 2.41 (m, 4H, CH₂N pirrolidine); 1.85 (m, 2H, OCH₂CH₂CH₂N); 1.65 (m, 4H, CH₂CH₂N pirrolidine); 1.23 (d, 6H, CHMe₂);

N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl}acetamide

¹H-NMR (DMSO-d₆) δ ppm: 12.1 (bs, 1H, CONH); 7.19 (t, 1H, H5 Ph); 7.13 (d, 1H, thiazole CH); 6.7-6.9 (m, 3H, H2, H4, H6 Ph); 3.95 (t, 2H, OCH₂CH₂CH₂N); 3.66 (s, 2H, COCH₃); 3.08 (m, 1H, CHMe₂); 2.15-2.45 (m, 10H, OCH₂CH₂CH₂N+piperazine); 2.11 (s, 3H, NMe); 1.82 (m, 2H, OCH₂CH₂CH₂N); 1.22 (d, 6H, CHMe₂).
2-{3-[2-(dimethylamino)ethoxy]phenyl}-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide

¹H-NMR (DMSO-d₆) δ ppm: 12.08 (bs, 1H, CONH); 7.2-6.90 (m,

5H, Ph+thiazole CH); 4.00 (t, 2H, OCH₂CH₂N); 3.66 (s, 2H, COCH₂); 3.07 (m, 1H, CHMe₂); 2.59 (t, 2H, OCH₂CH₂N); 2.11 (s, 3H, NMe); 2.19 (s, 6H, Me₂N); 1.22 (d, 6H, CHMe₂);

2-{3-[3-(dimethylamino)propoxy]phenyl}-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide

¹H-NMR (DMSO-d₆) δ ppm: 12.05 (bs, 1H, CONH); 7.19-6.79 (m, 5H, Ph+thiazole CH); 3.95 (t, 2H, OCH₂CH₂CH₂N); 3.66 (s, 2H, COCH₂); 3.08 (m, 1H, CHMe₂); 2.32 (t, 2H, OCH₂CH₂CH₂N); 2.11 (s, 3H, NMe₂); 1.81 (m, 2H, OCH₂CH₂CH₂N); 1.22 (d, 6H, CHMe₂).

Example 25

Preparation of 2-[N-[2'-N'-(ethoxycarbonyl-methyl)-amino]-acetyl]-amino-5-bromo-thiazole

A solution of N-(5-bromo-1,3-thiazol-2-yl)-2-bromoacetamide (0.35 g, 1.17 mmol) in DMF (5 ml) was added dropwise to a solution of glycine ethyl ester hydrochloride (0.33 g, 2.33 mmol) and triethylamine (0.49 ml, 3.5 mmol) in DMF (10 ml). After 3 hours at room temperature, the reaction mixture was heated at 40°C for about 5 hours and then diluted with water and extracted with methylene chloride. The combined organic layers were washed with brine, dried, concentrated and chromatographed on silica gel using cyclohexane:ethyl acetate 7:3 as eluent. The title compound was obtained as a colourless solid (0.15 g, 43%)

m.p. 115-116°C

¹H-NMR (DMSO-d₆) δ ppm: 7.46 (s, 1H, H4thiaz), 4.05 (q, 2H, OCH₂CH₃), 3.49 (s, 2H, NHCOCH₂), 3.4 (s, 2H, NHCH₂), 1.18 (t, 3H, OCH₂CH₃).

Analogously, the following compound can be prepared:

2-anilino-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide: m.p. 143-145°C

¹H-NMR (DMSO-d₆) δ ppm: 11.92 (s, 1H, NHCO), 7.13 (s, 1H, H4thiaz), 7.06-6.6 (m, 5H, Ph), 6.0 (t, 1H, NHCH₂), 3.95 (d, 2H, NHCH₂), 3.08 (m, 1H, CHMe₂), 1.23 (d, 6H, CHMe₂).

Example 26**Preparation of N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-bromophenyl)acetamide**

- 5 To a suspension of resin N-Cyclohexylcarbodiimide N'-methylpolystyrene (0.251 g, 2.39 mmol g⁻¹, 0.6 mmol), previously washed with DCM (3X5 ml), in DCM (4 ml) at room temperature, 2-bromophenylacetic acid (0.086 g, 0.4 mmol) was added. After 10 min., a solution of 2-amino-5-
- 10 isopropyl-1,3-thiazole (0.0284 g, 0.2 mmol) in DCM (4 ml) was added. The mixture was shaken for 24 hours at room temperature, the resin filtered and washed with DCM (3X10 ml). The filtrate were combined, washed with water, 5% HCl, water, saturated sodium bicarbonate and water, dried
- 15 over sodium sulfate and evaporated.

¹H-NMR (DMSO-d⁶) δ ppm: 10.05 (s broad, 1H, NHCOCH₂), 7.6-7.2 (m, 4H, Ar), 7.08 (s, 1H, H4thiaz), 3.98 (s, 2H, NHCOCH₂), 3.11 (m, 1H, CHMe₂), 1.31 (d, 6H, CHMe₂)

- 20 All the compounds were characterised by Mass Spectroscopy (MS). LC-MS confirmed that in each case the principle component had a molecular ion corresponding to the expected product.

- 25 Chromatography: Reverse phase HPLC with UV detection were run.

Mobile A: water (0.1% TFA)

Mobile B: acetonitrile:water 95:5 (0.1% TFA)

Flow rate: 1ml/min

- 30 Gradient: 10-100% B in 12 minutes, hold 100% B 3 min, return 10% B in 5 min

Detection: UV monitor 215, 254 and 300 nm

Sample were prepared as dilute solutions in acetonitrile (1-1.5 mM).

- 35 The compounds showed an HPLC area % ranging from 40 to 100%.

Starting from the suitable carboxylic acid, the following compounds can be prepared:

- 5 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,3,4,5,6-pentafluorophenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-chlorophenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-nitrophenyl)acetamide;
10 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-trifluoromethylphenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-methoxyphenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,5-dimethoxyphenyl)acetamide;
15 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,5-difluorophenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4,5-trimethoxyphenyl)acetamide;
20 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,6-dichlorophenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-chloro-6-fluorophenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,5-dimethoxyphenyl)acetamide;
25 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,5-difluorophenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,5-bis-trifluoromethylphenyl)acetamide;
30 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methylthiophenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methoxyphenyl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-bromophenyl)acetamide;
35 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-chlorophenyl)acetamide;

- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-trifluoromethylphenyl)acetamide;
- 5 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methylphenyl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-trifluoromethylphenyl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-chlorophenyl)acetamide;
- 10 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methoxyphenyl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-dinitrophenyl)acetamide;
- 15 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-dichlorophenyl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-difluorophenyl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide;
- 20 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-dichlorophenyl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-difluorophenyl)acetamide;
- 25 2-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide;
- 2-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2,2-diphenylacetamide;
- 30 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-nitrophenoxy)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)propanamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-isobutylphenyl)propanamide;
- 35 N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxo-2-phenylacetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-phenylpentanamide;

- (E, Z)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-2-butenamide;
N-(5-isopropyl-1,3-thiazol-2-yl)bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide;
- 5 N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl)butanamide;
tert-butyl (1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethylcarbamate;
(1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethyl acetate;
- 10 (1S)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethyl acetate;
2-(acetylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide;
(R)-2-(methoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide;
- 15 3,3,3-trifluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxy-2-phenylpropanamide;
2-(2,4-dinitrophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 20 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(5-benzyloxy-1H-indol-3-yl)acetamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methoxy-2-methyl-1H-indol-3-yl)acetamide;
2-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxoacetamide;
- 25 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
4-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)butanamide;
- 30 N-(5-isopropyl-1,3-thiazol-2-yl)-3-(2-thienyl)propanamide
2-(5-chloro-1-benzothiophen-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
2-(1-benzothiophen-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 35 2-[2-(formylamino)-1,3-thiazol-4-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)-2-(methoxyimino)acetamide;
2-{2-[(2-chloroacetyl)amino]-1,3-thiazol-4-yl}-N-(5-isopropyl-1,3-thiazol-2-yl)-2-(methoxyimino)acetamide;

- 2-chloro-N-(4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}-1,3-thiazol-2-yl)acetamide;
ethyl 2-({[2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-(1H-pyrazol-3-yl)ethylidene]amino}oxy)acetate;
- 5 N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxo-4-(4-methylphenyl)butanamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-nitrophenyl)butanamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenylbutanamide;
- 10 benzyl 4-[(5-isopropyl-1,3-thiazol-2-yl)amino]-4-oxobutylcarbamate;
4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)butanamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-methoxy-1-naphthyl)-4-oxobutanamide;
- 15 3-(2-chlorophenoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
3-(4-methylphenoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
- 20 3-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
3-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-methylpentanamide;
3-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
- 25 3-(4-methoxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
3-phenyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-5-oxo-5-phenylpentanamide;
- 30 2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethyl acetate;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide;
1-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)cyclopentanecarboxamide;
- 35 1-phenyl-N-(5-isopropyl-1,3-thiazol-2-yl)cyclopentanecarboxamide;

- 2-(3-bromo-4-methoxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 2-(2-nitro-4-trifluoromethylphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 5 5-cyclohexyl 1-(4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}benzyl) (2S)-2-[(tert-butoxycarbonyl)amino]pentanedioate;
- 2-(5,6-dimethyl-1H-benzimidazol-1-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 10 2-[5-(4-chlorophenyl)-2H-1,2,3,4-tetraazol-2-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-[5-(1-pyrrolidinyl)-2H-1,2,3,4-tetraazol-2-yl]acetamide;
- N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methyl-1-benzothiophen-2-yl)acetamide;
- 15 N-(5-isopropyl-1,3-thiazol-2-yl)-4,4-bis(4-methylphenyl)-3-butenamide;
- 2-cyclopropyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- N-{4-bromo-6-[(5-isopropyl-1,3-thiazol-2-yl)amino]-6-oxohexyl}benzamide;
- 20 2-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- benzyl 6-[(5-isopropyl-1,3-thiazol-2-yl)amino]-6-oxohexylcarbamate;
- N~1~- (5-isopropyl-1,3-thiazol-2-yl)-N~4~- (2-propynyl)-2-butenediamide;
- 25 4-(2,4-dimethylphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide;
- 4-(4-benzyloxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide;
- 30 4-(thiophen-2-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide;
- benzyl 2-[[(benzyloxy) carbonyl] amino]-5-[(5-isopropyl-1,3-thiazol-2-yl) amino]-5-oxopentanoate;
- 4-(1H-indol-3-yl)-N-{3-[(5-isopropyl-1,3-thiazol-2-yl) amino]-3-oxopropyl}butanamide;
- 35 4-[[(5-isopropyl-1,3-thiazol-2-yl) amino] carbonyl]phenyl 4-chlorobenzenesulfonate;

- N-(5-isopropyl-1,3-thiazol-2-yl)-4-{[(2-methoxyanilino)carbonyl]amino}benzamide;
4-{[2-(isopropylsulfonyl)acetyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
- 5 N-(5-isopropyl-1,3-thiazol-2-yl)-4-{[2-(phenylsulfanyl)acetyl]amino}benzamide;
4-[(diethylamino)sulfonyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
- 10 3,5-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
3-{[(2-fluoroanilino)carbonyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1-phenyl-5-propyl-1H-pyrazole-4-carboxamide;
- 15 3-chloro-4-(isopropylsulfonyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-5-(methylsulfanyl)-2-thiophenecarboxamide;
3-iodo-4-(isopropylsulfonyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-5-(methylsulfanyl)-2-thiophenecarboxamide;
2-{[(4-chlorophenyl)sulfonyl]methyl}-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methyl-1,3-thiazole-5-carboxamide;
- 20 5-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-(trifluoromethyl)-3-furamide;
3,5-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
3,4-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
- 25 2,4-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2,3-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
3-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
- 30 3-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-chloro-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
5-bromo-2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
- 35 2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2,4-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;

- 3,4-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2,3,4,5,6-pentafluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-methyl-3-nitrobenzamide;
5 N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-nitrobenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-nitrobenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dimethyl-4-nitrobenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxy-2-nitrobenzamide;
10 N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-2-nitrobenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxy-3-nitrobenzamide;
15 N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-4-nitrobenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dinitrobenzamide;
5-{{(5-isopropyl-1,3-thiazol-2-yl)amino}carbonyl}-2-nitrophenyl octanoate;
20 N-(5-isopropyl-1,3-thiazol-2-yl)-2-nitrobenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-nitrobenzamide;
4-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-3-nitrobenzamide;
4-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-nitrobenzamide;
2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-nitrobenzamide;
25 5-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-nitrobenzamide;
2-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)-5-nitrobenzamide;
4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-3-nitrobenzamide;
4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-nitrobenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-nitro-4-
30 (trifluoromethyl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-bis(trifluoromethyl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2,6-bis(trifluoromethyl)benzamide;
35 N-(5-isopropyl-1,3-thiazol-2-yl)-2-(trifluoromethyl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3-(trifluoromethyl)benzamide;

- 3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide;
2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-3-(trifluoromethyl)benzamide;
5 5-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-3-(trifluoromethyl)benzamide;
2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide;
4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-3-(trifluoromethyl)benzamide;
10 methyl 2-[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}benzoate;
4-cyano-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
3-cyano-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
15 N-(5-isopropyl-1,3-thiazol-2-yl)-3-methylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-methylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-methylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-vinylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-(2-phenylethynyl)benzamide;
20 N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-4-methylbenzamide;
2-benzyl-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenethylbenzamide;
25 N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenylbenzamide;
4-(tert-butyl)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-isopropylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-pentylbenzamide;
30 3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,4-dimethylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dimethylbenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-(methylsulfonyl)benzamide;
35 3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxybenzamide;

- 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxybenzamide;
5-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxybenzamide;
- 5 N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,4-dimethoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dimethoxybenzamide;
- 10 N-(5-isopropyl-1,3-thiazol-2-yl)-2,4-dimethoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2,3-dimethoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3-phenoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenoxybenzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenoxybenzamide;
- 15 2-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3,4,5-trimethoxybenzamide;
3,4-diethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
3,4,5-triethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 20 N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-4-(methoxymethoxy)benzamide;
4-butoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-propoxybenzamide;
4-isopropoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
- 25 N-(5-isopropyl-1,3-thiazol-2-yl)-1,3-benzodioxole-5-carboxamide;
4-(benzyloxy)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-(2-cyclohexen-1-yloxy)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
- 30 N-(5-isopropyl-1,3-thiazol-2-yl)-4-(trifluoromethoxy)benzamide;
4-(difluoromethoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-
- 35 (methylsulfanyl)benzamide;
2-[(4-chlorophenyl)sulfinyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;

- N-(5-isopropyl-1,3-thiazol-2-yl)-2-[(4-nitrophenyl)sulfinyl]benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-[(4-methylphenyl)sulfonyl]-3-nitrobenzamide;
5 N-(5-isopropyl-1,3-thiazol-2-yl)-3-[(trifluoromethyl)sulfanyl]benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxy-4-(methylsulfanyl)benzamide;
2-[(2-cyanophenyl)sulfanyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
10 N-1~,N-1~-diethyl-3,6-difluoro-N-2~-(5-isopropyl-1,3-thiazol-2-yl)phthalamide;
4-formyl-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2-formyl-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
15 4-[(2,5-dimethoxyanilino)carbonyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-(hydroxymethyl)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-nitrobenzyl acetate;
20 4-[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-nitrobenzyl 4-(acetylamino)-3-iodobenzoate;
4-(acetylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-4-[(2-phenylacetyl)amino]benzamide;
25 4-(acetylamino)-3-iodo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-amino-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
4-(dimethylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
30 3-(dimethylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
2-(methylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(trifluoromethyl)anilino]benzamide;
35 3-[(5-bromo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;

- N-(5-isopropyl-1,3-thiazol-2-yl)-4-(1H-pyrrol-1-yl)benzamide;
2,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)isonicotinamide;
5 2-(4-bromophenyl)-6-(4-iodophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)isonicotinamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(trifluoromethyl)anilino]nicotinamide;
5,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide;
10 2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-6-methylnicotinamide;
2,6-dichloro-5-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide
N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenoxy nicotinamide;
15 N-(5-isopropyl-1,3-thiazol-2-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2,6-dimethoxynicotinamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-quinoxalinecarboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-pyrazinecarboxamide;
20 N-(5-isopropyl-1,3-thiazol-2-yl)-8-quinolinecarboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-4-quinolinecarboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-1-phenyl-1H-pyrazole-4-carboxamide;
25 N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-1H-pyrazole-3-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1H-pyrazole-4-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
30 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methyl-1,3-thiazole-5-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-9H-fluorene-1-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-7-methoxy-1-benzofuran-2-carboxamide;
35 N-(5-isopropyl-1,3-thiazol-2-yl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide;
2-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)-1-naphthamide;

- 4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-1-naphthamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-naphthamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-9,10-dioxo-9,10-dihydro-2-anthracenecarboxamide;
- 5 N-(5-isopropyl-1,3-thiazol-2-yl)-9-oxo-9H-fluorene-4-carboxamide
N-(5-isopropyl-1,3-thiazol-2-yl)-9-oxo-9H-fluorene-1-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-8-oxo-5,6,7,8-tetrahydro-
- 10 2-naphthalenecarboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1,3-dioxo-1,3-dihydro-2-benzofuran-5-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-5-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-4-carboxamide;
- 15 N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-2-phenyl-1H-indole-5-carboxamide;
2-butyl-N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-1H-indole-5-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-6-carboxamide;
- 20 N-(5-isopropyl-1,3-thiazol-2-yl)-5-methoxy-1H-indole-2-carboxamide;
1-allyl-2-butyl-N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-5-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-1H-indole-2-
- 25 carboxamide;
1-benzyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-1H-indole-5-carboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-1H-1,2,3-benzotriazole-5-carboxamide;
- 30 N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dimethyl-4-isoxazolecarboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3-thiophenecarboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-thiophenecarboxamide;
- 35 N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-thiophenecarboxamide;
5-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)-2-thiophenecarboxamide;



- N-(5-isopropyl-1,3-thiazol-2-yl)-3-[(2,3,3-trichloroacryloyl)amino]-2-thiophenecarboxamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-5-(4-nitrophenyl)-2-
5 furamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-5-(2-nitrophenyl)-2-furamide;
5-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide;
10 N-(5-isopropyl-1,3-thiazol-2-yl)-5-[3-(trifluoromethyl)phenyl]-2-furamide;
5-(4-chloro-2-nitrophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide;
N-(5-isopropyl-1,3-thiazol-2-yl)-5-(4-methyl-2-
15 nitrophenyl)-2-furamide
5-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide;
tert-butyl (1S)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-1-methyl-2-oxoethylcarbamate
20 tert-butyl (1S,2S)-1-[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]-2-methylbutylcarbamate
tert-butyl 2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
tert-butyl (1S)-5-amino-1-[[(5-isopropyl-1,3-thiazol-2-
25 yl)amino]carbonyl]pentylcarbamate
tert-butyl 4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]butylcarbamate
tert-butyl 1-[[(5-isopropyl-1,3-thiazol-2-
30 yl)amino]carbonyl]-3-(tritylamino)propylcarbamate
tert-butyl (1S)-1-(benzyloxymethyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
tert-butyl (1S)-1-benzyl-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
35 tert-butyl (1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-(benzylthiomethyl)ethylcarbamate
benzyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-[(5-isopropyl-1,3-thiazol-2-yl)amino]-4-oxobutanoate










- tert-butyl (2S)-2-[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]-1-pyrrolidinecarboxylate
- tert-butyl (1S)-1-(1H-indol-3-ylmethyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
- 5 tert-butyl (1S)-1-[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]-3-(methylsulfanyl)propylcarbamate
- tert-butyl (1S)-2-benzyloxy-1-[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]propylcarbamate
- tert-butyl (1S)-1-(4-benzyloxybenzyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
- 10 tert-butyl (1S)-1-[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]-2-methylpropylcarbamate
- tert-butyl (1S)-1-[[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl]-3-methylbutylcarbamate and
- 15 benzyl (4S)-4-[(tert-butoxycarbonyl)amino]-5-[(5-isopropyl-1,3-thiazol-2-yl)amino]-5-oxopentanoate.










Following the same procedure as reported in Example 3, the compounds described in the table (I) below can be prepared:










20











Table I










MOLSTRUCTURE	m p °C	¹ H-NMR	Sol vent
		12.23 (s broad, 1H, <u>NHCOCH</u> ₂), 8.22-7.62 (m, 4H, Ar), 7.15 (s, 1H, H4thiaz), 3.91 (s, 2H, <u>NHCOCH</u> ₂), 3.08 (m, 1H, <u>CHMe</u> ₂), 1.22 (d, 6H, <u>CHMe</u> ₂)	DMSO-d ⁶
		9.81 (s broad, 1H, <u>NHCOCH</u> ₂), 7.5-7.3 (m, 4H, Ar), 7.11 (s, 1H, H4thiaz), 4.83 (s, 1H, <u>NHCOCH</u>), 3.44 (s, 3H, Ome), 3.11 (m, 1H, <u>CHMe</u> ₂), 1.3 (d, 6H, <u>CHMe</u> ₂)	DMSO-d ⁶










	124 - 125	12.06 (s broad, 1H, NHCO), 7.13 (s, 1H, H4thiaz) 6.92-6.81 (m, 3H, Ar), 3.72 (s, 3H, OMe), 3.70 (s, 3H, OMe), 3.61 (s, 2H, NHCOCH ₂), 3.07 (m, 1H, CHMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	77- 78	12.05 (s broad, 1H, NHCO), 7.38-7.29 (m, 5H, Ar), 7.12 (s, 1H, H4thiaz), 4.95 (s, 1H, CHOMe), 3.23 (s, 2H, CHOMe), 3.05 (m, 1H, CHMe ₂), 1.20 (d, 6H, CHMe ₂)	DMSO-d ⁶
	136 - 137	12.08 (s broad, 1H, NHCOCH ₂), 7.28 (d, 2H, Ar), 7.13 (s, 1H, H4thiaz), 7.1 (d, 2H, Ar), 3.65 (s, 2H, NHCOCH ₂), 3.06 (m, 1H, CHMe ₂), 2.98 (s, 6H, NMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	130 - 131	12.22 (s, 1H, NHCO), 7.85-7.48 (m, 7H, Ar), 7.14 (s, 1H, H4thiaz), 3.89 (s, 2H, CH ₂ CO), 3.07 (m, 1H, CHMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	130 - 131	12.16 (s, 1H, NHCO), 7.52-7.29 (m, 4H, Ar), 7.14 (s, 1H, H4thiaz), 3.73 (s, 2H, CH ₂ CO), 3.08 (m, 1H, CHMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	177 - 178	8.07-7.48 (m, 7H, Ar), 7.15 (s, 1H, H4thiaz), 4.22 (s, 2H, CH ₂ CO), 3.06 (m, 1H, CHMe ₂), 1.20 (d, 6H, CHMe ₂)	DMSO-d ⁶
	223 - 224	12.61 (s, 1H, NHCO), 7.69-7.51 (m, 4H, Ar), 7.19 (s, 1H, H4thiaz), 4.55 (dd, 1H, CHCO), 3.08 (m, 1H, CHMe ₂), 2.89 (m, 2H, COCH ₂ CH), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	105 - 106	12.50 (s, 1H, NHCO), 7.53-7.51 (m, 5H, Ar), 7.18 (s, 1H, H4thiaz), 6.12 (d, 1H, J _{H-F} = 46.8, CHF), 3.09 (m, 1H, CHMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	150 - 152	11.20 (s broad, 1H, NHCO), 7.28-7.07 (m, 5H, Ar+H4thiaz), 3.80 (s, 2H, CH ₂ CO), 3.13 (m, 1H, CHMe ₂), 1.32 (d, 6H, CHMe ₂)	DMSO-d ⁶

	164 - 166	11.45 (s broad, 1H, <u>NHCO</u>), 7.37-7.14 (m, 5H, Ar+ H4thiaz), 3.88 (s, 2H, <u>NHCOCH₂</u>), 3.12 (m, 1H, <u>CHMe₂</u>), 1.32 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	98- 100	8.35 (s broad, 1H, <u>NHCO</u>), 7.40 (m, 5H, Ar), 6.99 (s, 1H, H4thiaz), 3.10 (m, 1H, <u>CHMe₂</u>), 1.78 (m, 2H, <u>CH₂</u>), 1.29 (m, 2H, <u>CH₂</u>), 1.25 (d, 6H, <u>CHMe₂</u>)	CDCl ₃
	130 - 132	12.06 (s broad, 1H, <u>NHCOCH₂</u>), 7.13 (s, 1H, H4thiaz), 6.86-6.75 (m, 3H, Ar), 5.96 (s, 2H, <u>OCH₂O</u>), 3.60 (s, 2H, <u>NHCOCH₂</u>), 3.05 (m, 1H, <u>CHMe₂</u>), 1.22 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	100 - 102	12.1 (s broad, 1H, <u>NHCOCH₂</u>), 7.2-7 (m, 4H, Ar+ H4thiaz), 3.64 (s, 2H, <u>NHCOCH₂</u>), 3.07 (m, 1H, <u>CHMe₂</u>), 2.8-1.97 (m, 6H, -CH ₂ CH ₂ CH ₂ -), 1.22 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	98- 100	12.06 (s broad, 1H, <u>NHCO</u>), 7.3 (m, 5H, Ar), 7.03 (s, 1H, H4thiaz), 3.79 (q, 1H, <u>CHMe</u>), 3.10 (m, 1H, <u>CHMe₂</u>), 1.59 (d, 3H, <u>CHMe</u>), 1.30 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	167 - 169	10 (s broad, 1H, <u>NHCOCH₂</u>), 7.6-7.4 (m, 9H, Ar), 7.04 (s, 1H, H4thiaz), 3.84 (s, 2H, <u>NHCOCH₂</u>), 3.11 (m, 1H, <u>CHMe₂</u>), 1.31 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	115 - 116	12.06 (s broad, 1H, <u>NHCO</u>), 7.26 (m, 5H, Ar), 6.99 (s, 1H, H4thiaz), 3.79 (q, 1H, <u>CHMe</u>), 3.10 (m, 1H, <u>CHMe₂</u>), 1.59 (d, 3H, <u>CHMe</u>), 1.30 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	112 - 114	12.06 (s broad, 1H, <u>NHCO</u>), 7.33 (m, 5H, Ar), 7.11 (s, 1H, H4thiaz), 3.93 (q, 1H, <u>CHMe</u>), 3.07 (m, 1H, <u>CHMe₂</u>), 1.40 (d, 3H, <u>CHMe</u>), 1.22 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	124 - 126	12.01 (s broad, 1H, <u>NHCO</u>), 7.11-6-65 (m, 5H, Ar+H4thiaz), 3.55 (s, 2H, <u>NHCOCH₂</u>), 2.83 (s, 6H, <u>NMe₂</u>), 2.56 (d, 2H, <u>CH₂iPr</u>), 1.74 (m, 1H, <u>CHMe₂</u>), 0.87 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶


	139 - 141	9.90 (s broad, 1H, <u>NHCO</u>), 7.04 (s, 1H, H4thiaz), 6.78 (m, 3H, Ar), 5.96 (s, 2H, <u>OCH₂O</u>), 3.72 (s, 2H, <u>NHCOCH₂</u>), 2.60 (d, 2H, <u>CH₂iPr</u>), 1.85 (m, 1H, <u>CHMe₂</u>), 0.93 (d, 6H, <u>CHMe₂</u>)	CDCl ₃
	175 - 177	12.0 (s broad, 1H, <u>NHCO</u>), 7.28 (m, 6H, <u>CH₂Ph</u> +H4thiaz), 7.08-6.64 (m, 4H, Ar), 4.04 (s, 2H, <u>CH₂Ph</u>), 3.53 (s, 2H, <u>NHCOCH₂</u>), 2.82 (s, 6H, <u>NMe₂</u>)	DMSO-d ⁶
	88- 90	12.08 (s broad, 1H, <u>NHCO</u>), 7.20-6.81 (m, 5H, Ar+H4thiaz), 4.01 (dd, 2H, <u>OCH₂CH₂OMe</u>), 3.68 (s, 2H, <u>NHCOCH₂</u>), 3.61 (dd, 2H <u>OCH₂CH₂OMe</u>), 3.3 (s, 3H, <u>OCH₂CH₂OMe</u>), 3.05 (m, 1H, <u>CHMe₂</u>), 1.22 (s, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	230 - 231	12.81 (s broad, 1H, <u>NHCO</u>), 8.63-7.79 (m, 3H, Ar), 7.71 (s, 2H, NH ₂), 7.24 (s, 1H, H4thiaz), 3.12 (m, 1H, <u>CHMe₂</u>), 1.27 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	181 - 182	12.47 (s broad, 1H, <u>NHCO</u>), 8.13-7.37 (m, 4H, Ar), 7.23 (s, 1H, H4thiaz), 3.13 (m, 1H, <u>CHMe₂</u>), 1.27 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
		12.0 (s broad, 1H, <u>NHCO</u>), 8.89-7.82 (m, 4H, Ar), 7.27 (s, 1H, H4thiaz), 3.13 (m, 1H, <u>CHMe₂</u>), 1.28 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	263 - 264	12.74 (s broad, 1H, <u>NHCO</u>), 8.11-8.0 (2s, 2H, Ar), 7.82 (s, 2H, NH ₂), 7.24 (s, 1H, H4thiaz), 3.15 (m, 1H, <u>CHMe₂</u>), 1.27 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	204 - 206	12.6 (s broad, 1H, <u>NHCO</u>), 8.06-7.60 (m, 3H, Ar), 7.23 (s, 1H, H4thiaz), 3.12 (m, 1H, <u>CHMe₂</u>), 1.27 (d, 6H, <u>CHMe₂</u>)	DMSO-d ⁶
	148 - 150	8.54-8.31 (m, 3H, Ar), 6.98 (s, 1H, H4thiaz), 3.43 (s, 3H, <u>SO₂Me</u>), 3.14 (m, 1H, <u>CHMe₂</u>), 1.35 (d, 6H, <u>CHMe₂</u>)	CDCl ₃

	173 - 175	8.16-8.06 (2d, 4H, Ar), 7.25 (s, 1H, H4thiaz), 3.88 (s, 3H, COOMe), 3.14 (m, 1H, CHMe ₂), 1.28 (d, 6H, CHMe ₂)	DMSO-d ⁶
	164 - 166	8.50-7.86 (m, 3H, Ar), 7.24 (s, 1H, H4thiaz), 3.15 (m, 1H, CHMe ₂), 1.28 (d, 6H, CHMe ₂)	DMSO-d ⁶
	178 - 179	12.4 (s broad, 1H, NHCO), 8.12-7.21 (m, 3H, Ar), 7.22 (s, 1H, H4thiaz), 3.2-2.48 (m, 5H, CHMe ₂ , + piperazine), 2.22 (s, 3H, NMe), 1.27 (d, 6H, CHMe ₂)	DMSO-d ⁶
		12.6 (s broad, 1H, NHCO), 7.73-7.57 (m, 3H, Ar), 7.22 (s, 1H, H4thiaz), 3.15 (m, 1H, CHMe ₂), 1.27 (d, 6H, CHMe ₂)	DMSO-d ⁶
		12.6 (s broad, 1H, NHCO), 8.16-8.05 (m, 4H, Ar), 7.24 (s, 1H, H4thiaz), 3.13 (m, 1H, CHMe ₂), 2.62 (s, 3H, COMe), 1.28 (d, 6H, CHMe ₂)	DMSO-d ⁶
	207 - 209	9.4 (s broad, 1H, NHCO), 8.3 (s, 1H, NH), 7.55-6.98 (m, 6H, indole+H4thiaz), 3.96 (s, 2H, COCH ₂), 3.10 (m, 1H, CHMe ₂), 1.30 (d, 6H, CHMe ₂)	CDCl ₃
	116 - 118	9.80 (s broad, 1H, NHCO), 7.37-7.05 (m, 3H, Ar), 7.04 (d, 1H, H4thiaz), 3.84 (s, 2H, COCH ₂), 3.11 (m, 1H, CHMe ₂), 1.32 (d, 6H, CHMe ₂)	CDCl ₃
	148 - 150	10.20 (s broad, 1H, NHCO), 7.28-7.01 (m, 4H, Ar+H4thiaz), 4.02 (s, 2H, COCH ₂), 3.13 (m, 1H, CHMe ₂), 1.32 (d, 6H, CHMe ₂)	CDCl ₃
	170 - 172	12.05 (s broad, 1H, NHCO), 10.82 (s, 1H, NH), 7.48-6.90 (m, 5H, indole+H4thiaz), 3.74 (s, 2H, COCH ₂), 3.06 (m, 1H, CHMe ₂), 2.36 (s, 3H, Me), 1.21 (d, 6H, CHMe ₂)	DMSO-d ⁶
	163 - 165	12.07 (s broad, 1H, NHCO), 7.57-7.01 (m, 6H, indole+H4thiaz), 3.79 (s, 2H, COCH ₂), 3.74 (s, 3H, NMe), 3.05 (m, 1H, CHMe ₂), 1.21 (d, 6H, CHMe ₂)	DMSO-d ⁶

	155 - 157	10.20 (s broad, 1H, NHCO), 7.88-7.40 (m, 5H, Ar), 6.95 (s, 1H, H4thiaz), 4.04 (s, 2H, COCH ₂), 3.07 (m, 1H, CHMe ₂), 1.27 (d, 6H, CHMe ₂)	DMSO-d ⁶
	234 - 236	11.3 (s broad, 1H, NHCO), 7.52-6.28 (m, 5H, Ar+H4thiaz), 3.93 (s, 2H, COCH ₂), 3.87 (s, 3H, OMe), 3.10 (m, 1H, CHMe ₂), 1.27 (d, 6H, CHMe ₂)	DMSO-d ⁶
	161 - 163	12.19 (s, 1H, NHCO), 8.49-7.34 (m, 4H, Ar), 7.12 (s, 1H, H4thiaz), 2.56 (d, 2H, CH ₂ iPr), 1.75 (m, 1H, CHMe ₂), 0.86 (d, 6H, CHMe ₂)	DMSO-d ⁶
	166 - 168	12.20 (s, 1H, NHCO), 8.48-7.24 (m, 10H, 2Xar+H4thiaz), 4.06 (s, 2H, CH ₂ Ph), 3.77 (s, 2H, CH ₂ CO)	DMSO-d ⁶
	164 - 167	8.63-7.9 (m, 5H, Ar), 7.11 (s, 1H, H4thiaz), 3.85 (s, 2H, COCH ₂), 3.15 (m, 1H, CHMe ₂), 1.29 (d, 6H, CHMe ₂)	CDCl ₃
		11.6 (s broad, 1H, NHCO), 7.10 (s, 1H, H4thiaz), 3.67 (s, 3H, CH ₃ OCO), 3.15 (m, 1H, CHMe ₂), 2.60 (m, 2H, CH ₂ CH ₂ CH ₂), 2.46 (m, 2H, CH ₂ CH ₂ CH ₂), 2.09 (m, 2H, CH ₂ CH ₂ CH ₂), 1.34 (d, 6H, CHMe ₂)	CDCl ₃
	114 - 117	10.6 (s broad, 1H, NHCO), 7.36 (m, 5H, Ar), 7.10 (s, 1H, H4thiaz), 6.61 (d, 1H, J=15.8, CH=CHPh), 6.36 (dt, 1H, J=15.8, J=7.3, CH=CHPh), 3.43 (dd, 2H, J=7.3, 1.3, COCH ₂), 3.14 (m, 1H, CHMe ₂), 1.33 (d, 6H, CHMe ₂)	CDCl ₃
	217 - 220	12.09 (s broad, 1H, NHCO), 11.5 (s, 1H, NH), 7.78-7.16 (m, 4H, indole), 7.13 (s, 1H, H4thiaz), 3.78 (s, 2H, COCH ₂), 3.07 (m, 1H, CHMe ₂), 1.21 (d, 6H, CHMe ₂)	DMSO-d ⁶
	222 - 225 dec	12.07 (s, 1H, NHCO), 11.03 (s, 1H, NH), 7.3-6.80 (m, 5H, indole+H4thiaz), 3.77 (s, 2H, COCH ₂), 3.06 (m, 1H, CHMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶

	172 - 173	12.25 (s, 1H, NHCO), 8.02-7.4 (m, 4H, Ar), 7.15 (s, 1H, H4thiaz), 4.0 (s, 2H, COCH ₂), 3.07 (m, 1H, CHMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	203 - 204	12.05 (s, 1H, NHCO), 10.77 (s, 1H, NH), 7.22-6.70 (m, 5H, indole+ H4thiaz), 3.75 (s, 2H, COCH ₂), 3.72 (s, 3H, OMe), 3.07 (m, 1H, CHMe ₂), 1.22 (d, 6H, CHMe ₂)	DMSO-d ⁶
	163 - 164	12.89 (s, 1H, NHCO), 10.75 (s, 1H, NH), 7.12-6.97 (m, 5H, indole+ H4thiaz), 3.10 (m, 1H, CHMe ₂), 3.01 (t, 2H, CH ₂ CH ₂ CO), 2.78 (t, 2H, CH ₂ CH ₂ CO), 1.25 (d, 6H, CHMe ₂)	DMSO-d ⁶
	186 - 187	12.7 (s broad, 1H, NHCO), 8.18 (d, 1H, J=7.8, Ar), 7.71 (d, 1H, J=7.8, Ar), 7.24 (s, 1H, H4thiaz), 3.15 (m, 1H, CHMe ₂), 1.27 (d, 6H, CHMe ₂)	DMSO-d ⁶
		10.8 (s broad, 1H, NHCO), 7.45 (s, 1H, H4thiaz), 3.33 (m, 1H, CHMe ₂), 2.54 (m, 2H, CH ₂ CHMe ₂), 2.42 (m, 1H, CH ₂ CHMe ₂), 1.53 (d, 6H, CH ₂ CHMe ₂), 1.21 (d, 6H, CHMe ₂)	CDCl ₃
		12.4 (s broad, 1H, NHCO), 8.05-7.51 (m, 5H, Ph), 7.23 (s, 1H, H4thiaz), 3.13 (m, 1H, CHMe ₂), 1.28 (d, 6H, CHMe ₂)	DMSO-d ⁶
		11.8 (s broad, 1H, NHCO), 7.11 (s, 1H, H4thiaz), 3.08 (m, 1H, CHMe ₂), 2.25 (d, 2H, CH ₂ CO), 2.42 (m, 1H, CH ₂ CHMe ₂), 1.23 (d, 6H, CHMe ₂), 1.8-0.8 (m, 11H, cyclohexyl)	DMSO-d ⁶
		8.13 (d, 1H, H3fur), 7.84 (d, 1H, H5fur), 7.25 (d, 1H, H4thiaz), 6.69 (dd, 1H, H4fur), 7.45 (s, 1H, H4thiaz), 3.20 (m, 1H, CHMe ₂), 1.39 (d, 6H, CHMe ₂)	CDCl ₃
		12.7 (s broad, 1H, NHCO), 7.54-6.82 (m, 3H, H4thiaz+furane), 3.10 (m, 1H, CHMe ₂), 1.26 (d, 6H, CHMe ₂),	DMSO-d ⁶


In the claims of this application and in the description of the invention, except where the context requires otherwise due to express language or necessary implication, the words "comprise" or variations such as
5 "comprises" or "comprising" are used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. The use of a compound which is a 2-amino-1,3-thiazole derivative of formula (I)

5



wherein

R is isopropyl;

10 R₁ is an optionally further substituted group selected from:

i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl;

ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;

15 iii) aryl or arylcarbonyl;

iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;

v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;

20 vi) an optionally protected amino acid residue; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for treating cell proliferative disorders associated with an altered cell cycle dependent kinase activity.

25

2. Use according to claim 1 wherein the said cell proliferative disorder is selected from the group consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative disorders.

30

3. Use according to claim 2 wherein the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratacarcinoma, osteosarcoma, xenoderoma


35

pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

4. Use according to claim 1 wherein the cell
5 proliferative disorder is selected from the group
consisting of benign prostrate hyperplasia, familial
adenomatosis polyposis, neuro-fibromatosis, psoriasis,
vascular smooth cell proliferation associated with
atherosclerosis, pulmonary fibrosis, arthritis
10 glomerulonephritis and post-surgical stenosis and
restenosis.

5. Use according to any one of the preceding claims
wherein the medicament enables tumor angiogenesis and
15 metastasis inhibition.

6. A compound which is a 2-amino-1,3-thiazole
derivative of formula (I)




wherein

R is isopropyl;

R₁ is an optionally further substituted group selected
25 from:

- i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl;
- ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;
- iii) aryl or arylcarbonyl;
- 30 iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;
- v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;
- vi) an optionally protected amino acid residue;
- 35 or a pharmaceutically acceptable salt thereof; for use as a medicament; provided that R₁ is not a methyl group.

7. A compound which is a 2-amino-1,3-thiazole derivative of formula (I)



wherein

5 R is isopropyl;

R₁ is an optionally further substituted group selected from:

i) straight or branched C₁-C₈ alkyl or C₂-C₆ alkenyl;

ii) 3 to 6 membered carbocycle or 5 to 7 membered

10 heterocycle ring;

iii) aryl or arylcarbonyl;

iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;

v) arylalkenyl with from 2 to 6 carbon atoms within the

15 straight or branched alkenyl chain;

vi) an optionally protected amino acid residue;

or a pharmaceutically acceptable salt thereof;

provided that:

a) R₁ is not methyl.

20

8. A compound of formula (I), according to claim 7, wherein R is isopropyl and R₁ is an optionally substituted group selected from straight or branched C₁-C₄ alkyl or alkenyl, aryl or arylalkyl with from 1 to 4 carbon atoms
25 within the alkyl chain or it is an optionally protected amino acid residue.

9. A compound of formula (I) according to claim 7 wherein R is isopropyl and R₁ is a straight or branched
30 C₁-C₆ alkyl group or an aryl group, each R₁ being unsubstituted or substituted by hydroxy, alkylthio, alkoxy, amino, alkylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, alkylcarbonyl, alkylsulfonyl, alkoxycarbonyl, carboxy or aryl which is unsubstituted or

substituted by one or more hydroxy, halogen, nitro,
alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino,
dialkylamino, N-alkyl-piperazinyl, 4-morpholinyl,
arylamino, cyano, alkyl, phenyl, aminosulfonyl,
5 aminocarbonyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl
or carboxy groups, or R is an aryl group which is
unsubstituted or substituted by one or more hydroxy,
halogen, nitro, alkoxy, aryloxy, alkylthio, arylthio,
amino, alkylamino, dialkylamino, N-alkyl-piperazinyl, 4-
10 morpholinyl, arylamino, cyano, alkyl, phenyl,
aminosulphonyl, aminocarbonyl, alkylcarbonyl,
arylcarbonyl, alkoxycarbonyl or carboxy groups;
or a pharmaceutically acceptable salt thereof;
provided that:
15 a) R_1 is not methyl.

10. A compound of formula (I) according to any one of the
preceding claims, whenever appropriate in the form of a
pharmaceutically acceptable salt, selected from the group
20 consisting of:

1. 2-N-[2-(3-pyridyl)-acetyl-amino]-5-isopropyl-thiazole;
2. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-
hydroxyphenyl)acetamide;
3. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-
25 methoxyphenyl)acetamide;
4. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-
chlorophenyl)acetamide;
5. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-
hydroxyphenyl)acetamide;
- 30 6. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-
dihydroxyphenyl)acetamide;
7. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-hydroxy-3-
methoxyphenyl)acetamide;

8. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methoxyphenyl)acetamide;
9. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-chlorophenyl)acetamide;
- 5 10. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-acetamide;
11. N-(5-isopropyl-thiazol-2-yl)-4-sulfamoyl-benzamide;
12. N-(5-isopropyl-1,3-thiazol-2-yl)-butanamide;
13. 2-[3-(2-chloroethoxy)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 10 14. 2-(4-aminophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
15. 4-amino-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide;
16. 2-(2-amino-1,3-thiazol-4-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 15 17. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(4-morpholinyl)propoxy]phenyl}acetamide;
18. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[2-(4-morpholinyl)ethoxy]phenyl}acetamide;
19. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(1-pyrrolidinyl)propoxy]phenyl}acetamide;
- 20 20. N-(5-isopropyl-1,3-thiazol-2-yl)-2-{3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl}acetamide;
21. 2-{3-[2-(dimethylamino)ethoxy]phenyl}-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide;
- 25 22. 2-{3-[3-(dimethylamino)propoxy]phenyl}-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
23. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(2-methoxyethoxy)-phenyl]acetamide
24. 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-methyl-1-piperazinyl)benzamide
- 30 25. 2-anilino-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
26. (R)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylpropanamide

27. (S)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylpropanamide
28. N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
29. 2,5-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 5 30. 3,5-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
31. 3,4-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
32. 2,4-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
33. 2,3-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
34. 3-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 10 35. 2-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
36. 4-iodio-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
37. 3-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
38. 4-chloro-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 15 39. 5-bromo-2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
40. 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
41. 2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
42. 4-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 20 43. 3-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
44. 2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
45. 4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
46. 2,4-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
47. 3,4-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 25 48. 2,3,4,5,6-pentafluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide

- 49.N- (5-isopropyl-1,3-thiazol-2-yl) -4-methyl-3-nitrobenzamide
- 50.N- (5-isopropyl-1,3-thiazol-2-yl) -5-methyl-2-nitrobenzamide
- 5 51.N- (5-isopropyl-1,3-thiazol-2-yl) -3-methyl-2-nitrobenzamide
- 52.N- (5-isopropyl-1,3-thiazol-2-yl) -3,5-dimethyl-4-nitrobenzamide
- 53.N- (5-isopropyl-1,3-thiazol-2-yl) -4-methoxy-2-nitrobenzamide
- 10 54.N- (5-isopropyl-1,3-thiazol-2-yl) -3-methoxy-2-nitrobenzamide
- 55.N- (5-isopropyl-1,3-thiazol-2-yl) -4-methoxy-3-nitrobenzamide
- 15 56.N- (5-isopropyl-1,3-thiazol-2-yl) -3-methoxy-4-nitrobenzamide
- 57.N- (5-isopropyl-1,3-thiazol-2-yl) -3,5-dinitrobenzamide
- 58.5- { [(5-isopropyl-1,3-thiazol-2-yl) amino] carbonyl } -2-nitrophenyl octanoate
- 20 59.N- (5-isopropyl-1,3-thiazol-2-yl) -3-nitrobenzamide
- 60.N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitrobenzamide
- 61.N- (5-isopropyl-1,3-thiazol-2-yl) -4-nitrobenzamide
- 62.N- (5-isopropyl-1,3-thiazol-2-yl) -4- (methylsulfonyl) -3-nitrobenzamide
- 25 63.4-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-nitrobenzamide
- 64.6-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-nitrobenzamide
- 65.4-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitrobenzamide
- 30 66.2-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-nitrobenzamide

- 67.5-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitrobenzamide
- 68.2-bromo-N- (5-isopropyl-1,3-thiazol-2-yl) -5-nitrobenzamide
- 5 69.4-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-nitrobenzamide
- 70.4-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitrobenzamide
- 71.N- (5-isopropyl-1,3-thiazol-2-yl) -2-nitro-4-(trifluoromethyl)benzamide
- 10 72.N- (5-isopropyl-1,3-thiazol-2-yl) -3,5-bis(trifluoromethyl)benzamide
- 73.N- (5-isopropyl-1,3-thiazol-2-yl) -2,6-bis(trifluoromethyl)benzamide
- 15 74.N- (5-isopropyl-1,3-thiazol-2-yl) -2-(trifluoromethyl)benzamide
- 75.N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl)benzamide
- 76.3-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-(trifluoromethyl)benzamide
- 20 77.2-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl)benzamide
- 78.5-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl)benzamide
- 25 79.2-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-(trifluoromethyl)benzamide
- 80.4-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -3-(trifluoromethyl)benzamide
- 81.methyl 4- { [(5-isopropyl-1,3-thiazol-2-yl) amino] carbonyl } benzoate
- 30 82.methyl 2- { [(5-isopropyl-1,3-thiazol-2-yl) amino] carbonyl } benzoate
- 83.4-cyano-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
- 84.3-cyano-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide

85. N- (5-isopropyl-1,3-thiazol-2-yl) -3-methylbenzamide
86. N- (5-isopropyl-1,3-thiazol-2-yl) -2-methylbenzamide
87. N- (5-isopropyl-1,3-thiazol-2-yl) -4-methylbenzamide
88. N- (5-isopropyl-1,3-thiazol-2-yl) -4-vinylbenzamide
5 89. N- (5-isopropyl-1,3-thiazol-2-yl) -4- (2-phenylethynyl) benzamide
90. N- (5-isopropyl-1,3-thiazol-2-yl) -3-methoxy-4-methylbenzamide
91. 2-benzyl-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
10 92. N- (5-isopropyl-1,3-thiazol-2-yl) -2-phenethylbenzamide
93. N- (5-isopropyl-1,3-thiazol-2-yl) -2-phenylbenzamide
94. N- (5-isopropyl-1,3-thiazol-2-yl) -4-phenylbenzamide
95. 4- (tert-butyl) -N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
15 96. N- (5-isopropyl-1,3-thiazol-2-yl) -4-isopropylbenzamide
97. N- (5-isopropyl-1,3-thiazol-2-yl) -4-pentylbenzamide
98. 3-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-methylbenzamide
99. N- (5-isopropyl-1,3-thiazol-2-yl) -3,4-dimethylbenzamide
20 100. N- (5-isopropyl-1,3-thiazol-2-yl) -3,5-dimethylbenzamide
101. 4-acetyl-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
102. N- (5-isopropyl-1,3-thiazol-2-yl) -4- (methylsulfonyl) benzamide
25 103. 5- (aminosulfonyl) -2,4-dichloro-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
104. 5- (aminosulfonyl) -4-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) benzamide
105. 3-fluoro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-methoxybenzamide
30 106. 3-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -4-methoxybenzamide
107. 5-chloro-N- (5-isopropyl-1,3-thiazol-2-yl) -2-methoxybenzamide

108. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methoxybenzamide
109. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxybenzamide
110. N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxybenzamide
111. N-(5-isopropyl-1,3-thiazol-2-yl)-3,4-
5 dimethoxybenzamide
112. N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-
dimethoxybenzamide
113. N-(5-isopropyl-1,3-thiazol-2-yl)-2,4-
dimethoxybenzamide
10 114. N-(5-isopropyl-1,3-thiazol-2-yl)-2,3-
dimethoxybenzamide
115. N-(5-isopropyl-1,3-thiazol-2-yl)-3-phenoxybenzamide
116. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenoxybenzamide
117. N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenoxybenzamide
15 118. 2-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
119. 4-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
120. N-(5-isopropyl-1,3-thiazol-2-yl)-3,4,5-
trimethoxybenzamide
121. 3,4-diethoxy-N-(5-isopropyl-1,3-thiazol-2-
20 yl)benzamide
122. 3,4,5-triethoxy-N-(5-isopropyl-1,3-thiazol-2-
yl)benzamide
123. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methoxy-4-
(methoxymethoxy)benzamide
25 124. 4-butoxy-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
125. N-(5-isopropyl-1,3-thiazol-2-yl)-4-propoxybenzamide
126. 4-isopropoxy-N-(5-isopropyl-1,3-thiazol-2-
yl)benzamide
127. N-(5-isopropyl-1,3-thiazol-2-yl)-1,3-benzodioxole-5-
30 carboxamide
128. 4-(benzyloxy)-N-(5-isopropyl-1,3-thiazol-2-
yl)benzamide
129. 4-(2-cyclohexen-1-yloxy)-N-(5-isopropyl-1,3-thiazol-
2-yl)benzamide

130. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(trifluoromethoxy)benzamide
131. 4-(difluoromethoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 5 132. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(methylsulfanyl)benzamide
133. 2-[(4-chlorophenyl)sulfinyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
134. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[(4-nitrophenyl)sulfinyl]benzamide
- 10 135. N-(5-isopropyl-1,3-thiazol-2-yl)-4-[(4-methylphenyl)sulfonyl]-3-nitrobenzamide
136. N-(5-isopropyl-1,3-thiazol-2-yl)-3-[(trifluoromethyl)sulfanyl]benzamide
- 15 137. N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxy-4-(methylsulfanyl)benzamide
138. 2-[(2-cyanophenyl)sulfanyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
139. N-1~,N-1~-diethyl-3,6-difluoro-N-2--(5-isopropyl-1,3-thiazol-2-yl)phthalamide
- 20 140. 4-formyl-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
141. 2-formyl-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
142. 4-{[(2,5-dimethoxyanilino)carbonyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 25 143. 4-(hydroxymethyl)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
144. 4-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-nitrobenzyl acetate
145. 4-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-nitrobenzyl 4-(acetylamino)-3-iodobenzoate
- 30 146. 4-(acetylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
147. N-(5-isopropyl-1,3-thiazol-2-yl)-4-[(2-phenylacetyl)amino]benzamide

148. 4-(acetylamino)-3-iodo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
149. 4-amino-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
150. 4-(dimethylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 5 151. 3-(dimethylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
152. 2-(methylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 10 153. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(trifluoromethyl)anilino]benzamide
154. 3-{[(5-bromo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 15 155. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(1H-pyrrol-1-yl)benzamide
156. 2,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)isonicotinamide
157. 2-(4-bromophenyl)-6-(4-iodophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)isonicotinamide
- 20 158. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[3-(trifluoromethyl)anilino]nicotinamide
159. 2,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide
- 25 160. 5,6-dichloro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide
161. 2-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)-6-methylnicotinamide
162. 2,6-dichloro-5-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)nicotinamide
- 30 163. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenoxy nicotinamide
164. N-(5-isopropyl-1,3-thiazol-2-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide

165. N-(5-isopropyl-1,3-thiazol-2-yl)-2,6-dimethoxynicotinamide
166. N-(5-isopropyl-1,3-thiazol-2-yl)-2-quinoxalinecarboxamide
- 5 167. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-pyrazinecarboxamide
168. N-(5-isopropyl-1,3-thiazol-2-yl)-8-quinolinecarboxamide
169. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-4-quinolinecarboxamide
- 10 170. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-1-phenyl-1H-pyrazole-4-carboxamide
171. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-1H-pyrazole-3-carboxamide
- 15 172. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-pyrazole-4-carboxamide
173. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide
174. 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methyl-1,3-thiazole-5-carboxamide
- 20 175. N-(5-isopropyl-1,3-thiazol-2-yl)-9H-fluorene-1-carboxamide
176. N-(5-isopropyl-1,3-thiazol-2-yl)-7-methoxy-1-benzofuran-2-carboxamide
- 25 177. N-(5-isopropyl-1,3-thiazol-2-yl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide
178. 2-ethoxy-N-(5-isopropyl-1,3-thiazol-2-yl)-1-naphthamide
- 30 179. 4-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-1-naphthamide
180. N-(5-isopropyl-1,3-thiazol-2-yl)-2-naphthamide
181. N-(5-isopropyl-1,3-thiazol-2-yl)-9,10-dioxo-9,10-dihydro-2-anthracenecarboxamide

182. N-(5-isopropyl-1,3-thiazol-2-yl)-9-oxo-9H-fluorene-4-carboxamide
183. N-(5-isopropyl-1,3-thiazol-2-yl)-9-oxo-9H-fluorene-1-carboxamide
- 5 184. N-(5-isopropyl-1,3-thiazol-2-yl)-8-oxo-5,6,7,8-tetrahydro-2-naphthalenecarboxamide
185. N-(5-isopropyl-1,3-thiazol-2-yl)-1,3-dioxo-1,3-dihydro-2-benzofuran-5-carboxamide
186. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-5-carboxamide
- 10 187. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-4-carboxamide
188. N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-2-phenyl-1H-indole-5-carboxamide
- 15 189. 2-butyl-N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-1H-indole-5-carboxamide
190. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-6-carboxamide
191. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methoxy-1H-indole-2-carboxamide
- 20 192. 1-allyl-2-butyl-N-(5-isopropyl-1,3-thiazol-2-yl)-1H-indole-5-carboxamide
193. N-(5-isopropyl-1,3-thiazol-2-yl)-1-methyl-1H-indole-2-carboxamide
- 25 194. 1-benzyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-1H-indole-5-carboxamide
195. N-(5-isopropyl-1,3-thiazol-2-yl)-1H-1,2,3-benzotriazole-5-carboxamide
196. N-(5-isopropyl-1,3-thiazol-2-yl)-3,5-dimethyl-4-isoxazolecarboxamide
- 30 197. N-(5-isopropyl-1,3-thiazol-2-yl)-3-thiophenecarboxamide
198. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-thiophenecarboxamide

199. N-(5-isopropyl-1,3-thiazol-2-yl)-5-methyl-2-thiophenecarboxamide
200. 5-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)-2-thiophenecarboxamide
- 5 201. N-(5-isopropyl-1,3-thiazol-2-yl)-3-[(2,3,3-trichloroacryloyl)amino]-2-thiophenecarboxamide
202. 5-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide
203. N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide
204. N-(5-isopropyl-1,3-thiazol-2-yl)-5-(4-nitrophenyl)-2-furamide
- 10 205. N-(5-isopropyl-1,3-thiazol-2-yl)-5-(2-nitrophenyl)-2-furamide
206. 5-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide
- 15 207. N-(5-isopropyl-1,3-thiazol-2-yl)-5-[3-(trifluoromethyl)phenyl]-2-furamide
208. 5-(4-chloro-2-nitrophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide
209. N-(5-isopropyl-1,3-thiazol-2-yl)-5-(4-methyl-2-nitrophenyl)-2-furamide
- 20 210. 5-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)-2-furamide
211. tert-butyl (1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethylcarbamate
- 25 212. (1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethyl acetate
213. (1S)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethyl acetate
214. (R,S)-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
- 30 215. (R)-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
216. (S)-2-fluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide

217. 2-(acetylamino)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
218. (R,S)-2-(methoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
- 5 219. (R)-2-(methoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
220. (S)-2-(methoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
- 10 221. 3,3,3-trifluoro-N-(5-isopropyl-1,3-thiazol-2-yl)-2-methoxy-2-phenylpropanamide
222. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(1-naphthyl)acetamide
223. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-naphthyl)acetamide
- 15 224. 2-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
225. 2-(1,3-benzodioxol-4-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
226. 2-(2,4-dinitrophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 20 227. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-methyl-1H-indol-3-yl)acetamide
228. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(1-methyl-1H-indol-3-yl)acetamide
- 25 229. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(5-methoxy-1H-indol-3-yl)acetamide
230. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(5-benzyloxy-1H-indol-3-yl)acetamide
231. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methoxy-2-methyl-1H-indol-3-yl)acetamide
- 30 232. 2-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxoacetamide
233. 2-(5-bromo-1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide

234. 2-(5-fluoro-1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
235. 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 5 236. 3-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
237. 4-(1H-indol-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)butanamide
238. N-(5-isopropyl-1,3-thiazol-2-yl)-3-(2-thienyl)propanamide
- 10 239. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-thienyl)acetamide
240. N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxo-2-(2-thienyl)acetamide
- 15 241. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-thienyl)acetamide
242. 2-(5-chloro-1-benzothiophen-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
243. 2-(1-benzothiophen-3-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 20 244. 2-[2-(formylamino)-1,3-thiazol-4-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)-2-(methoxyimino)acetamide
245. 2-{2-[(2-chloroacetyl)amino]-1,3-thiazol-4-yl}-N-(5-isopropyl-1,3-thiazol-2-yl)-2-(methoxyimino)acetamide
- 25 246. 2-chloro-N-(4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}-1,3-thiazol-2-yl)acetamide
247. ethyl 2-({[2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-(1H-pyrazol-3-yl)ethylidene]amino}oxy)acetate
248. 2-(2-furyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxoacetamide
- 30 249. 2-(5-bromo-3-pyridinyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
250. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide

251. N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenyl-3-butenamide
252. N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxo-4-(4-methylphenyl)butanamide
- 5 253. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-nitrophenyl)butanamide
254. N-(5-isopropyl-1,3-thiazol-2-yl)-4-phenylbutanamide
255. benzyl 4-[(5-isopropyl-1,3-thiazol-2-yl)amino]-4-oxobutylcarbamate
- 10 256. methyl 5-[(5-isopropyl-1,3-thiazol-2-yl)amino]-5-oxopentanoate
257. 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)butanamide
258. N-(5-isopropyl-1,3-thiazol-2-yl)-4-(4-methoxy-1-naphthyl)-4-oxobutanamide
- 15 259. 3-(2-chlorophenoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
260. 3-(4-methylphenoxy)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
- 20 261. 3-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
262. 3-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
263. N-(5-isopropyl-1,3-thiazol-2-yl)-4-methylpentanamide
- 25 264. 3-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
265. 3-(4-methoxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
266. 3-chloro-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
- 30 267. 3-phenyl-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
268. 2-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
269. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methylbutanamide
270. N-(5-isopropyl-1,3-thiazol-2-yl)-5-oxo-5-phenylpentanamide
- 35

271. 2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-phenylethyl acetate
272. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide
- 5 273. 1-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)cyclopentanecarboxamide
274. 1-phenyl-N-(5-isopropyl-1,3-thiazol-2-yl)cyclopentanecarboxamide
275. 2-(3-bromo-4-methoxyphenyl)-N-(5-isopropyl-1,3-
10 thiazol-2-yl)acetamide
276. 2-(2-nitro-4-trifluoromethylphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
277. 5-cyclohexyl 1-(4-{2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}benzyl) (2S)-2-[(tert-
15 butoxycarbonyl)amino]pentanedioate
278. 2-(5,6-dimethyl-1H-benzimidazol-1-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
279. 2-[5-(4-chlorophenyl)-2H-1,2,3,4-tetraazol-2-yl]-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 20 280. N-(5-isopropyl-1,3-thiazol-2-yl)-2-[5-(1-pyrrolidinyl)-2H-1,2,3,4-tetraazol-2-yl]acetamide
281. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methyl-1-benzothiophen-2-yl)acetamide
282. N-(5-isopropyl-1,3-thiazol-2-yl)-4,4-bis(4-
25 methylphenyl)-3-butenamide
283. 2-cyclopropyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
284. N-{4-bromo-6-[(5-isopropyl-1,3-thiazol-2-yl)amino]-6-oxohexyl}benzamide
- 30 285. 2-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
286. benzyl 6-[(5-isopropyl-1,3-thiazol-2-yl)amino]-6-oxohexylcarbamate
287. N~1~-(5-isopropyl-1,3-thiazol-2-yl)-N~4~-(2-
35 propynyl)-2-butenediamide

288. 4-(2,4-dimethylphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide
289. 4-(4-benzyloxyphenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide
- 5 290. 4-(thiphen-2-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-oxobutanamide
291. benzyl 2-([(benzyloxy)carbonyl]amino)-5-[(5-isopropyl-1,3-thiazol-2-yl)amino]-5-oxopentanoate
292. 4-(1H-indol-3-yl)-N-{3-[(5-isopropyl-1,3-thiazol-2-yl)amino]-3-oxopropyl}butanamide
- 10 293. 4-([(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}phenyl 4-chlorobenzenesulfonate
294. N-(5-isopropyl-1,3-thiazol-2-yl)-4-([(2-methoxyanilino)carbonyl]amino)benzamide
- 15 295. 4-{[2-(isopropylsulfonyl)acetyl]amino}-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
296. N-(5-isopropyl-1,3-thiazol-2-yl)-4-{[2-(phenylsulfonyl)acetyl]amino}benzamide
297. 4-[(diethylamino)sulfonyl]-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 20 298. 2-bromo-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
299. 3,5-difluoro-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
300. 3-([(2-fluoroanilino)carbonyl]amino)-N-(5-isopropyl-1,3-thiazol-2-yl)benzamide
- 25 301. N-(5-isopropyl-1,3-thiazol-2-yl)-1-phenyl-5-propyl-1H-pyrazole-4-carboxamide
302. 3-chloro-4-(isopropylsulfonyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-5-(methylsulfonyl)-2-thiophenecarboxamide
- 30 303. 3-iodo-4-(isopropylsulfonyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-5-(methylsulfonyl)-2-thiophenecarboxamide
304. 2-([(4-chlorophenyl)sulfonyl]methyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-4-methyl-1,3-thiazole-5-carboxamide
- 35

305. 5-(4-chlorophenyl)-N-(5-isopropyl-1,3-thiazol-2-yl)-
2-(trifluoromethyl)-3-furamide
306. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,3,4,5,6-
pentafluorophenyl)acetamide
- 5 307. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-
fluorophenyl)acetamide
308. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-
bromophenyl)acetamide
309. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-
10 chlorophenyl)acetamide
310. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-
nitrophenyl)acetamide
311. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-
trifluoromethylphenyl)acetamide
- 15 312. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-
methoxyphenyl)acetamide
313. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,5-
dimethoxyphenyl)acetamide
314. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,5-
20 difluorophenyl)acetamide
315. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4,5-
trimethoxyphenyl)acetamide
316. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,6-
dichlorophenyl)acetamide
- 25 317. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-chloro-6-
fluorophenyl)acetamide
318. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,5-
dimethoxyphenyl)acetamide
319. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,5-
30 difluorophenyl)acetamide
320. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,5-bis-
trifluoromethylphenyl)acetamide
321. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-
methylthiophenyl)acetamide


322. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methoxyphenyl)acetamide
323. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-bromophenyl)acetamide
- 5 324. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-chlorophenyl)acetamide
325. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-fluorophenyl)acetamide
326. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)acetamide
- 10 327. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-trifluoromethylphenyl)acetamide
328. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-methylphenyl)acetamide
- 15 329. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-dimethylaminophenyl)acetamide
330. 2-[1,1'-biphenyl]-4-yl-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
331. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-trifluoromethylphenyl)acetamide
- 20 332. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-bromophenyl)acetamide
333. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-chlorophenyl)acetamide
- 25 334. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-nitrophenyl)acetamide
335. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3-methoxyphenyl)acetamide
336. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-dinitrophenyl)acetamide
- 30 337. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-dichlorophenyl)acetamide
338. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2,4-difluorophenyl)acetamide

339. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide
340. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-dichlorophenyl)acetamide
- 5 341. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-difluorophenyl)acetamide
342. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide
343. 2-(2,3-dihydro-1H-inden-5-yl)-N-(5-isopropyl-1,3-thiazol-2-yl)acetamide
- 10 344. N-(5-isopropyl-1,3-thiazol-2-yl)-1-phenylcyclopropanecarboxamide
345. 2-cyclopentyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
- 15 346. 2-cyclohexyl-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenylacetamide
347. N-(5-isopropyl-1,3-thiazol-2-yl)-2,2-diphenylacetamide
348. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(2-nitrophenoxy)acetamide
- 20 349. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)propanamide
350. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl)propanamide
351. N-(5-isopropyl-1,3-thiazol-2-yl)-2-(4-isobutylphenyl)propanamide
- 25 352. N-(5-isopropyl-1,3-thiazol-2-yl)-2-oxo-2-phenylacetamide
353. N-(5-isopropyl-1,3-thiazol-2-yl)-3-methyl-2-phenylpentanamide
- 30 354. (E, Z)-N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl-2-butenamide
355. N-(5-isopropyl-1,3-thiazol-2-yl)bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide

356. N-(5-isopropyl-1,3-thiazol-2-yl)-3-oxo-1-indanecarboxamide
357. N-(5-isopropyl-1,3-thiazol-2-yl)-2-phenyl)butanamide
358. tert-butyl (1S)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-1-methyl-2-oxoethylcarbamate
- 5 359. tert-butyl (1S,2S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-methylbutylcarbamate
360. tert-butyl 2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
- 10 361. tert-butyl (1S)-5-amino-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}pentylcarbamate
362. tert-butyl 4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}butylcarbamate
- 15 363. tert-butyl 1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-3-(tritylamino)propylcarbamate
364. tert-butyl (1S)-1-(benzyloxymethyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
- 20 365. tert-butyl (1S)-1-benzyl-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
366. tert-butyl (1R)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxo-1-(benzylthiomethyl)ethylcarbamate
367. benzyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-[(5-isopropyl-1,3-thiazol-2-yl)amino]-4-oxobutanoate
- 25 368. tert-butyl (2S)-2-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-1-pyrrolidinecarboxylate
369. tert-butyl (1S)-1-(1H-indol-3-ylmethyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
- 30 370. tert-butyl (1S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-3-(methylsulfonyl)propylcarbamate
371. tert-butyl (1S)-2-benzyloxy-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}propylcarbamate
372. tert-butyl (1S)-1-(4-benzyloxybenzyl)-2-[(5-isopropyl-1,3-thiazol-2-yl)amino]-2-oxoethylcarbamate
- 35

373. tert-butyl (1S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-2-methylpropylcarbamate
374. tert-butyl (1S)-1-{[(5-isopropyl-1,3-thiazol-2-yl)amino]carbonyl}-3-methylbutylcarbamate
5 375. benzyl (4S)-4-[(tert-butoxycarbonyl)amino]-5-[(5-isopropyl-1,3-thiazol-2-yl)amino]-5-oxopentanoate
and the pharmaceutically acceptable salts thereof.

11. A process for producing a compound of formula (I), as
10 defined in any one of claims 6 to 10, which process
comprises reacting a compound of formula (II)



15

with a compound of formula (III)



- wherein R and R₁ are as defined in claim 7 and X is hydroxy
20 or a suitable leaving group;

and, if desired, converting a 2-amino-1,3-thiazole
derivative of formula (I) into another such derivative of
formula (I), and/or into a salt thereof.

- 25 12. A process according to claim 11 wherein X is hydroxy,
bromine or chlorine.

13. A pharmaceutical composition comprising one or more
pharmaceutically acceptable carriers and/or diluents and,
30 as the active principle, an effective amount of a compound
of formula (I) as defined in any one of claims 6 to 10.

14. A compound of formula (I) as defined in any one of
claims 6 to 10 wherein R₁ is optionally substituted in any
35 of the free positions by one or more groups, selected
from: halogen, nitro, oxo groups (=O), carboxy, cyano,
alkyl, perfluorinated alkyl, alkenyl, alkynyl, cycloalkyl,

aryl, heterocycyl; amino groups and derivatives thereof;
carbonylamino groups and derivatives thereof; oxygen-
substituted oximes; hydroxy groups and derivatives
thereof; carbonyl groups and derivatives thereof and
5 sulfurated derivatives.

15. A compound of formula (I) as defined in claim 14
wherein the amino groups or derivatives thereof are
alkylamino, alkoxycarbonylalkylamino, dialkylamino,
10 arylamino, diarylamino or arylureido.

16. A compound of formula (I) as defined in claim 14 or
claim 15 wherein the carbonylamino groups and derivatives
thereof are hydrogenocarbonylamino (HCONH-),
15 alkylcarbonylamino, alkenylcarbonylamino,
arylcarbonylamino or alkoxycarbonylamino.

17. A compound of formula (I) as defined in any one of
claims 14 to 16 wherein the oxygen-substituted oximes are
20 alkoxycarbonylalkoxyimino or alkoxyimino.

18. A compound of formula (I) as defined in any one of
claims 14 to 17 wherein the hydroxy groups and derivatives
thereof are alkoxy, aryloxy, alkylcarbonyloxy,
25 arylcarbonyloxy or cycloalkenyloxy.

19. A compound of formula (I) as defined in any one of
claims 14 to 18 wherein the carbonyl groups and
derivatives thereof are alkylcarbonyl, arylcarbonyl,
30 alkoxycarbonyl, aryloxy carbonyl, cycloalkyloxy carbonyl,
aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl.

20. A compound of formula (I) as defined in any one of
claims 14 to 19 wherein the sulfurated derivatives are
35 alkylthio, arylthio, alkylsulphonyl, arylsulphonyl,
alkylsulphinyl, arylsulphinyl, arylsulphonyloxy,

aminosulfonyl, alkylaminosulphonyl or
dialkylaminosulphonyl.

21. A method for treating cell proliferative disorders
5 associated with an altered cell cycle dependent kinase
activity which comprises administering an effective amount
of a compound of formula (I) as defined in any one of
claims 1 and 6 to 10 to a subject in need thereof.

10 22. Compounds of formula (I), processes for their
production, pharmaceutical compositions containing them or
uses or methods involving them, substantially as
hereinbefore described with reference to the accompanying
examples.

15

Dated this 1st day of August 2003

PHARMACIA & UPJOHN S.P.A.

By their Patent Attorneys

20 GRIFFITH HACK

Fellows Institute of Patent and
Trade Mark Attorneys of Australia

